[{"article": "Most head and neck cancers are linked to alcohol consumption and to smoking.\nThough there weren't enough data on decaf drinkers to draw conclusions, drinking tea -- even massive quantities -- was not protective.\nProbably not.\nInterestingly, the protective effect of coffee was not diminished in drinkers and smokers.\nWas it the caffeine?\n", "question": "Does the story commit disease-mongering?", "explanation": "Not applicable \u2013 there really wasn\u2019t any background given on the types of cancer in question. ", "answer": 2}, {"article": "UCH-L1 is released by brain nerves when they\u2019re stressed, and its levels rise more rapidly immediately after injury and peak at eight hours.\nBut there aren\u2019t good ways to distinguish between mild blows that don\u2019t require additional care and mild to moderate traumatic brain injury (TBI), which could have more serious consequences.\nAbout half them had brain-related injuries, and half had other traumas, including broken bones and chest injuries.\n\u201cI don\u2019t think a blood will be the be-all and end-all but it would be a beautiful tool for us to have in the clinic to support a lot of our decision making.\u201d\n\nTesting for levels of UCH-L1, for example, might be helpful for emergency medical teams in an ambulance trying to assess whether a patient has any serious head injuries, since its levels peak in the hours immediately after a trauma.\nPapa wanted to test several things about the blood test, including whether they were specific to brain injuries or whether they changed during any trauma to any part of the body.\n", "question": "Does the story commit disease-mongering?", "explanation": "No obvious disease mongering in this story. Concussions and traumatic brain injury are a serious public health issue.", "answer": 1}, {"article": "His \"tactile imaging system\" capitalizes on the fact that cancerous lumps tend to feel harder and less movable than harmless abnormalities such as fluid-filled cysts or fibrous nodules. The fist-sized, $1,000 machine \u2014 with an elastomer probe, a light, and a camera \u2014 acts like ultrasensitive fingertips. It measures the size, elasticity, and mobility of a breast lump, then a computer program converts the data into a score from 1 to 5, with scores under 2 likely to be benign.", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "Dr Weaver said: \"We have shown that all our patients in the study had their insulin doses reduced after taking metformin and have not suffered any serious adverse effect.\nIt is estimated around 400,000 people in the UK have the condition.\nThis follows previous laboratory work at Newcastle University which explored the mechanism behind metformin.\nFindings of the clinical trial are published today in the journal, Cardiovascular Diabetology.\nShe was enrolled on the clinical trial in the summer of 2013.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release does not appear to commit disease mongering.", "answer": 1}, {"article": ".\nThis study expands on the researchers' previous finding that dTMS reduced food cravings and induced weight loss in obese individuals.\nORLANDO--A new study finds that a noninvasive electromagnetic brain stimulation technique helps obese people lose weight, partly by changing the composition of their intestinal bacteria--the so-called gut microbiota.\n\"Our research shows the innovative ability of dTMS in exerting anti-obesity effects through alteration of the gut-brain axis.\"\nAfter five weeks of treatment, subjects receiving dTMS lost more than 3 percent of their body weight and more than 4 percent of their fat--significantly more than controls did, Luzi reported.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease mongering. Obesity is an increasing problem on both the individual and population-level scales. The release provides some context about why new obesity treatments are needed, as well as the possible role gut microbes might play in weight management.", "answer": 1}, {"article": "\"I know that I can just sort of be on my sits bones, instead of a funny arch with my stomach pushed out or my back arched in some strange way,\" says Rodriguez\n\nJosephine Gray is Rodriguez's teacher and is a certified instructor in Alexander Technique.\nResearch suggests an alternative therapy called Alexander Technique may be an effective way to treat back pain.\nBut there is evidence it can ease chronic low back pain over the long run.\nBut finding a remedy for back pain can be a lot like a guessing game.\nHe led a study of some 460 patients who were given Alexander lessons, massage, or the usual care of pain killers and exercise.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no significant disease mongering in this article. Chronic low back pain is a common problem for which there are limited effective treatments.\u00a0\n", "answer": 1}, {"article": "We need to assess these options before jumping to possible universal screening.\"\nAmong the 5,798 children who would not have been screened, nearly 10% had elevated LDL cholesterol levels (above 130 mg/dL), according to the study, published in the August issue of Pediatrics.\nIndeed, of all the children in the study whose LDL levels were above 160, one-third were in the group who would not have been screened.\nFurther, Neal says, the findings apply not only to heart-disease risk but also to the risk of diabetes, since high cholesterol at a young age is a strong predictor of prediabetes and diabetes.\nA new study finds that current guidelines for cholesterol screening in children may miss nearly 10% of those who have high levels of LDL, or bad cholesterol.\n", "question": "Does the story commit disease-mongering?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\n \nThe lead of the story focuses on the number of children with elevated cholesterol who might be missed based on current national guidelines and does not jump to the conclusion that these children would necessarily benefit from treatment. The story also reports that less than two percent of the children tested had cholesterol levels high enough that doctors might consider drug treatment. Oddly, the lead sentence says current guidelines \u201cmay miss nearly 10% of those who have high levels of LDL, or bad cholesterol,\u201d but the researchers put the figure at closer to a third. It may be that the reporter confused the proportion of children overall who had elevated cholesterol (about 10%) with the proportion of children with elevated cholesterol who would not have been tested under current guidelines (about a third.)\n", "answer": 0}, {"article": "Some research has suggested a link between lower levels of insulin in cerebrospinal fluid and the formation of plaques often found in the brain tissue of people with Alzheimer\u2019s.\nThe research described in Quick Study comes from credible, peer-reviewed journals.\nFIND THIS STUDY February issue of the Journal of Alzheimer\u2019s Disease (www.j-alz.com).\nNonetheless, conclusive evidence about a treatment's effectiveness is rarely found in a single study.\nCAVEATS The study involved a relatively small number of participants and lasted a short time; a larger and longer study would be needed to adequately test effectiveness and safety.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering here. And the story does a good job explaining the connection between Alzheimer\u2019s and memory loss.", "answer": 1}, {"article": "More adults and kids taking Prozac, known generically as fluoxetine, had at least a 50 percent improvement in scores on depression tests after six weeks compared to those assigned to take a placebo pill.\n\u201cDefinitely it doesn\u2019t look like antidepressants are placebos,\u201d he concluded.\nAbout 9,000 participants were included.\nStill, not everyone in the studies improved \u2014 on average, about five people had to be treated with one of the drugs for one person to feel better, and the benefits seemed to be diminished among some of the oldest patients.\nStill, Gibbons said that the improvement in symptoms for the average patient wasn\u2019t insignificant.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering about depression here.", "answer": 1}, {"article": "Eleven practitioners had increased bone density in their spine and hips, he reported in 2009, compared with seven controls who did not practice yoga.\nNo one knows these challenges better than Dr. Loren M. Fishman, a physiatrist at Columbia University who specializes in rehabilitative medicine.\nFurthermore, a special study of bone quality done on 18 of the participants showed that they had \u201cbetter internal support of their bones, which is not measured by a bone density scan but is important to resisting fractures,\u201d Dr. Fishman said.\nA pharmaceutical company is unlikely to fund a study that doesn\u2019t involve a drug, and in any event, the research requires a large group of volunteers tracked over a very long time.\nThe idea is not widely accepted in the medical community, but then, researchers know comparatively little about complementary medicine in general.\n", "question": "Does the story commit disease-mongering?", "explanation": "No evident disease mongering in this story, except to say that osteoporosis and it\u2019s precursor osteopenia are often heavily mongered diseases simply because bone density is one of many risk factors for hip fractures (that is treatable with drugs) but it is not the most important one. In fact, some argue that bone density is such a low predictor for hip fractures it is worthless as a measure of bone health and simply shouldn\u2019t be employed.", "answer": 1}, {"article": "\u201cCould we do a better job collectively?\u201d he asked.\nBecause the test comes with a small risk of a serious reaction, it should not be performed in very young children and pregnant women, among others.\nWhile most allergy patients are seen by these generalists, he says, many allergies are not adequately diagnosed.\nThe blood test is also part of a larger debate about who should be treating allergy sufferers.\n\u201cThere\u2019s been a longstanding fear of skin testing, and it turns off a lot of allergy sufferers from getting help,\u201d said Dr. Mitchell, the author of \u201cAllergy and Asthma Solution\u201d (Marlowe, 2006), which advocates oral immunotherapy, or allergy drops, instead of shots.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story commits disease mongering by not emphasizing that the blood and skin tests are only used in those with severe allergies. Most people with common pet or seasonal allergies will not require this kind of testing. Furthermore, the story overstates the risk that children with allergies have of\u00a0developing respiratory problems and asthma later on.", "answer": 0}, {"article": "; Nirubol Tosakulwong; Kent Bailey, Ph.D.; Julie Fields, Ph.D.; Lynne Shuster, M.D.\n\u201cThis study showed, for the first time, that the brain amyloid deposition \u2500 a hallmark of Alzheimer\u2019s disease \u2500 is reduced in newly postmenopausal women who received 17beta-Estradiol patch form of hormone therapy,\u201d says lead author Kejal Kantarci, M.D., a Mayo Clinic radiologist.\nThe authors are seeking funding to perform amyloid PET imaging at eight more Kronos Early Estrogen Prevention study sites around the U.S.\n\n\u201cIf our results are confirmed in the larger group of women, this finding has the potential to change the concepts for preventive interventions that drive the Alzheimer\u2019s disease field today,\u201d Dr. Kantarci says.\nThe researchers used positron emission tomography, also known as a PET scan, to look for the brain amyloid deposits three years after the trial ended.\nIn the study, women with APOE e4 \u2014 one form of the most common gene associated with late-onset Alzheimer's disease \u2014 had lower levels of amyloid deposits.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t exaggerate a condition. It states that declines in estrogen associated with menopause \u201cmay\u201d be associated with an increased risk of dementia. Unfortunately, that doesn\u2019t give readers a feel for the robustness of the relationship, or for the evidence supporting it.", "answer": 1}, {"article": "In 2016, he was ranked the No.\nThese results, published today online ahead of print in the American Journal of Medicine, with an accompanying editorial by the editor-in-chief, show that Plaque HD\u00ae, produced statistically significant reductions in dental plaque and inflammation throughout the body as measured by hs-CRP.\nIn the accompanying editorial titled, \"Can a Toothpaste Reduce Heart Attacks and Strokes?,\" Joseph S. Alpert, M.D., an internationally renowned cardiologist, noted the importance and timeliness of these findings and commented on how his father, a dentist, had told him even before he went to medical school, that dental health may affect heart attacks and strokes.\nIn this trial, all randomized subjects were given the same brushing protocol and received a 60-day supply of toothpaste containing either Plaque HD\u00ae or an identical non-plaque identifying placebo toothpaste.\nThe results released today from a randomized trial of a novel plaque identifying toothpaste, (Plaque HD\u00ae), show statistically significant reductions in dental plaque and inflammation throughout the body.\n", "question": "Does the news release commit disease-mongering?", "explanation": "This release illustrates a recurring problem with disease-oriented rather than patient-oriented evidence. The release ties dental plaque and hs-CRP test levels more tightly to heart attacks and strokes than is justified. It begins by stating, \u201cFor decades, research has suggested a link between oral health and inflammatory diseases affecting the entire body \u2014 in particular, heart attacks and strokes.\u201d But it doesn\u2019t explain how nuanced those links are. Indeed, the value of CRP testing is hotly debated. It is typically recommended only for people having a hard time deciding whether or not to begin statin drug treatment. The release strongly (and improperly) implies that everyone, regardless of their individual heart disease risk, would benefit from something that lowers hs-CRP levels. Indeed, almost 40 percent of the trial participants were dropped from the hs-CRP comparisons because their levels were already low. If researchers decided that more than a third of the trial participants were unlikely to see any meaningful reduction in their hs-CRP levels, the release should have noted that many people have no reason to think that this product could reduce their heart disease risk.", "answer": 0}, {"article": "The median age was 75 years (range 41to 94).\n\"Older patients are often not considered for radiation therapy due to concerns about their ability to tolerate treatment.\nElekta (EKTA-B.ST) today announced new data demonstrating stereotactic body radiation therapy (SBRT) is a safe treatment option for early-stage lung cancer patients aged 80 or older.\nThe results of our study clearly support the use of SBRT for elderly patients, especially those who may not be able to tolerate longer courses of radiotherapy or more invasive treatment options,\" says Meredith Giuliani, MBBS, FRCPC, MEd, a radiation oncologist in the Cancer Clinical Research Unit at Princess Margaret Cancer Centre, University Health Network in Toronto and lead study author.\n\"In addition to providing important support for using SBRT to treat early-stage lung cancer in elderly patients, these findings highlight the value of multi-institutional collaborations and large data sets that can provide statistically meaningful answers to critical questions about treatment outcome and guide clinical decision making.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in the release. But we also don\u2019t know the natural history of early stage lung cancer in this population. Does treatment really extend the quantity or quality of life? We expect it does, but nothing presented here supports SBRT compared to no treatment or other active treatments.", "answer": 1}, {"article": "\"She should talk to her doctor,\" Smith said.\nStudying the effectiveness of MRI screening on all three groups of women, Dr. Wendy DeMartini, an assistant professor of radiology at the University of Washington Medical School, said MRI imaging found proportionally more cancers in women who had been treated for breast cancer than in the women considered at very high risk.\nMONDAY, Nov. 29, 2010 (HealthDay News) -- Women who have had breast cancer should consider annual screening with breast MRI in addition to an annual mammogram, new research indicates.\nCurrently, the American Cancer Society recommends annual breast MRI plus mammography for women at very high risk for breast cancer, such as those with a known genetic mutation known as BRCA or those with a very strong family history.\nBut it takes no position on MRI imaging for women who have had breast cancer, saying there is not enough evidence to recommend one way or the other.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\nThe story does say that the American Cancer Society does not currently recommend MRI scans for most women with a history of breast cancer. However, it does not give readers the information they need to understand who this study is relevant to. It does not provide key details about the women who participated in the study. Was there something unusal about their cases that prompted them to get an MRI scan of their breasts? The researchers reported that 3 percent of the women with a personal history of breast cancer were found to have another tumor. That number seems quite high. The story should have told readers more about the women in the study and how they compare to the average woman who has had treatment for breast cancer. And again, it should not allow researchers to claim that MRI adds anything to conventional mammography when this study did not involve any such comparison.\n", "answer": 0}, {"article": "In Rothwell\u2019s study, published in The Lancet, researchers found the 20-year risk of death was reduced by about 10 percent for prostate cancer, 30 percent for lung cancer, 40 percent for colorectal or bowel cancer and 60 percent for oesophageal cancer in those taking aspirin.\nThe findings will fuel an already intense debate about the merits of taking aspirin, which increases the risk of bleeding in the stomach to around one patient in every thousand per year.\nAlastair Watson, professor of translational medicine at the University of East Anglia, said the study was an important step in scientists\u2019 understanding of how to prevent cancer.\nPeter Elwood, an expert on aspirin from Cardiff University\u2019s medical school who was not involved in this study, described aspirin as \u201ca remarkable drug.\u201d\n\n\u201cThis risk of a bleed is so small compared to the benefits,\u201d he told reporters.\nLONDON (Reuters) - Taking low doses of aspirin can reduce the risk of many kinds of cancer, scientists said on Tuesday, and the evidence is strong enough to suggest people over 40 should take it daily as protection.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\nThe story highlights suggestions that everyone over 40 begin taking aspirin in order to reduce the risk of many types of cancer, while minimizing concerns about the limitations of this study and the risks associated with aspirin. The voices included in this story form a cheering section for the universal use of aspirin.", "answer": 0}, {"article": "Scientists have slowed down the ageing process by implanting stem cells into the brains of animals, raising hopes for new strategies to combat age-related diseases and extend the human lifespan.\n\u201cHowever, if the mechanism is fundamental, you might expect to see effects when an intervention is based on it.\u201d\n\nPrevious experiments had already hinted that the hypothalamus, an almond-sized part of the brain in humans, played some role in the ageing process, but what it was remained unclear.\nThe work, described as a tour de force and a breakthrough by one leading expert, suggests that ageing across the body is controlled by stem cells that are found in the hypothalamus region of the brain in youth, but which steadily die off until they are almost completely absent in middle age.\nHaving proved that it was neural stem cells that were important for ageing, the scientists ran further tests to work out what the cells were doing.\nI can see a day when we are implanted with stem cells or treated with stem cell RNAs that improve our health and extend our lives.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story doesn\u2019t appear to commit disease mongering, though it could have pointed out that aging in and of itself is not a disease.", "answer": 1}, {"article": "A drug-coated stent made by Abbott Laboratories that is awaiting U.S. regulatory approval is as safe as, and potentially more effective than, the market-leading version of the heart device made by Boston Scientific Corp., according to findings presented Tuesday at the EuroPCR conference in Barcelona.\n\nClinical-trial data analyzed by Abbott two years after its Xience V stents were implanted in patients are likely to reassure investors and regulators about the product's long-term safety and could restore some investor confidence...", "question": "Does the story commit disease-mongering?", "explanation": "The story engaged in subtle disease mongering because in its discussion of the use for this new product to treat \u2018blocked blood vessels\u2019 it failed to acknowlege that in fact, national guidelines don\u2019t recommend the use of stents to treat all\u00a0blocked coronary arteries, only those through which flow is occluded 70% or more.", "answer": 0}, {"article": "Neuroblastomas are cancers that start in early nerve cells and commonly form in the tissue of the adrenal glands, near the kidneys.\nThis research is an excellent example of the collaboration between Nemours Children's Hospital and the University of Central Florida.\nAt no more than 100 nanometers, nanoparticles are exceedingly small.\n\"High-risk neuroblastoma can be resistant to traditional therapy, and survival can be poor.\nFunding of this work was supported by the Nemours Foundation along with the regional economic development initiative of the Florida High Tech Corridor.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in this news release.", "answer": 1}, {"article": "increases at age 4, although no cognitive benefit was seen in infants or 7-year-olds.\n\u201cAnd it might be of some help.\u201d\nHe said more research was needed, but for now, \u201cI think the market is running way out in front of the science.\u201d\n\nScientists agree that DHA, naturally transmitted to a fetus through the placenta in the last half of pregnancy, is important, probably to visual and brain development.\nShe said babies in her study might have received more DHA than those in this study.\n\u201cThere\u2019s no harm that we know of at all, in contrast to many antidepressants,\u201d he said.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering.\u00a0 Good quotes from chief of maternal-fetal medicine at a leading Boston hospital:\u00a0\u201cI think the market is running way out in front of the science.\u201d", "answer": 1}, {"article": "The women with hysterectomies who used estrogen alone had a 23 percent lower risk for breast cancer compared with those who had taken a placebo.\nDr. Chlebowski previously led research that showed cancer risks associated with combination hormone therapy, but he says the new data on estrogen alone show that in certain women, estrogen use to relieve menopausal symptoms is a \u201cgood choice.\u201d\n\n\u201cWhen you look at the debate, people are saying hormones are good or not good \u2014 it\u2019s been all or nothing.\nThe research, part of the landmark Women\u2019s Health Initiative study, is likely to surprise women and their doctors, who for years have heard frightening news about the risks of hormone therapy.\n\u201cI hope that separation will become clearer now.\u201d\n\n \n\n\n\nThis article appeared in print on Wednesday, April 6, 2011 on page A1.\n\u201cThe big message there is that the data look much more favorable for younger women and much riskier for older women,\u201d said Dr. LaCroix.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does a good job of discussing a variety of risks without exaggerating any of them. If anything, they may exaggerate the benefits in the headline.", "answer": 1}, {"article": "WASHINGTON\u2014People with mild Alzheimer\u2019s disease who started taking an experimental Eli Lilly & Co. drug earlier in the course of their disease fared better than patients who started later in a clinical trial.\n\nThe outcome may bolster the company\u2019s case that the drug, solanezumab, can slow the decline of memory and function in mild Alzheimer\u2019s patients, despite prior studies with negative results. But the new data aren\u2019t final proof of the drug\u2019s benefit\u2014a separate, continuing study due to end in late 2016 is designed to...", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "Gestational diabetes increases the mother\u2019s chances for high blood pressure disorders of pregnancy and the need for cesarean delivery, and the risk for cardiovascular disease and type 2 diabetes later in life.\nThe study appears in Scientific Reports.\nThe researchers analyzed records from the NICHD Fetal Growth Study, a large observational study that recruited more than 2,000 low-risk pregnant women from 12 U.S. clinical sites between 2009 and 2013.\nSimilarly, research is needed to determine whether lowering HbA1c with lifestyle changes, either in early pregnancy or before pregnancy, could reduce the risk for the condition.\nThe test is not currently recommended to diagnose gestational diabetes at any point in pregnancy.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No mongering, but no data about frequency of the disorder, either.", "answer": 2}, {"article": "But another finding from that study sheds an interesting light on one of 5-Hour Energy\u2019s central claims \u2014 that the energy shot, unlike competitors\u2019, produces \u201cNo Crash Later.\u201d\n\nAccording to the study, 24 percent of test participants who received 5-Hour Energy had reactions similar to a \u201cmoderately severe crash that left them extremely tired and in need of rest, another drink or some other action,\u201d lawsuit filings show.\nBut she declined to say why the results of the study, which was apparently conducted five years ago, had not yet appeared.\nAmong them: bringing out Lipovitan Junior, a caffeine-free version for children.\nWhatever the case, the energy drink boom has come full circle in Asia, the region where it started.\nMs. Lutz, the Living Essentials spokeswoman, said the bold \u201cNo Crash Later\u201d statement on product labels was followed by a special mark.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "The trials were conducted with colleagues from Monash University.\nOf the one-in-five people worldwide who will suffer from a gastrointestinal disorder in their lifetime, almost a third remain undiagnosed due to a lack of reliable tests available to gastroenterologists.\n\"The rate of false positive and false negative diagnosis that breath tests give is a real problem in gastroenterology,\" Berean, who is also Chief Technology Officer at Atmo Bioscience, said.\nStudy lead and capsule co-inventor Professor Kourosh Kalantar-zadeh said the results showed high sensitivity and signal-to-noise ratio in measuring the concentration of intestinal hydrogen, providing valuable information at the site of intestinal gas production.\nNew trials of a breakthrough swallowable sensor have revealed the device is 3,000 times more accurate than current technology used to diagnose many gut disorders.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release makes it sound like there is an epidemic of undiagnosed gastrointestinal disease occurring\u00a0worldwide:\nOf the one-in-five people worldwide who will suffer from a gastrointestinal disorder in their lifetime, almost a third remain undiagnosed due to lack of reliable tests available to gastroenterologists.\nBut the news release doesn\u2019t provide any source for this questionable claim.\nMoreover, the release suggests that that this technology will help \u201cdiagnose many gut disorders\u201d when, in reality \u2014 even if it does get marketed (like breath testing) \u2014\u00a0 it will likely only be applicable for a very short list of very uncommon gastrointestinal ailments listed HERE [Source: Johns Hopkins Medical School].", "answer": 0}, {"article": "He also keeps his blood pressure down by exercising and paying attention to his weight and diet.\nAt least two large studies have revealed an alarming trend among stroke patients, Koroshetz says.\nIf people knew about the link between dementia and high blood pressure, they might be more inclined to do something about it, Koroshetz says.\nAnd he says other people with high blood pressure should follow his lead.\nThe evidence is clearest for a type of dementia called vascular dementia.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story strongly suggets that people should take blood pressure medication to lower their risk of dementia. The evidence in the story wasn\u2019t strong enough to cross that line.\nAt the very least, the story should have provided links to the studies in this sentence: \u201cAt least two large studies have revealed an alarming trend among stroke patients.\u201d\nIt\u2019s also worth noting that the threshold for treatment is under debate, with some saying that blood pressure should be even lower than 130/80.\u00a0New suggestions like this \u2014 that BP control can lower dementia risk \u2014 may amplify such concerns by driving even more people in for treatment without a full grasp of the tradeoffs between potential benefits and potential harms.", "answer": 0}, {"article": "Corticosteroids are involved in a wide range of physiological processes in the body, including regulating metabolism, blood pressure and helping the body to cope with physical stress.\nThe researchers say that, with further research, these findings may one-day lead to improved therapies for other conditions that respond to steroid treatment, including asthma and rheumatoid arthritis.\nThe new treatment - expected to have fewer side effects than existing therapies - could help people with disorders of the adrenal gland whose bodies are unable to produce a class of steroids called corticosteroids.\nThe researchers tested the therapy in a small group of patients with Addison's disease.\nThe therapy could help people with conditions such as Addison's disease and congenital adrenal hyperplasia, who need steroid treatment to avoid the risk of potentially fatal illness during physical stress.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The researchers make it clear that they are not trying to cure a health problem but, rather, seek to offer a safer treatment regimen for individuals with adrenal gland disorders.", "answer": 1}, {"article": "For that reason, UV devices are often used for sterilization \u2014 for medical equipment in hospitals, for example, or drinking water for backcountry campers.\nBut conventional germicidal lamps aren\u2019t safe for humans to be around.\n\u201cThink about doctor\u2019s waiting rooms, schools, airports and airplanes\u2014any place where there\u2019s a likelihood for airborne viruses.\u201d And unlike the flu vaccine, he says, far-UVC light is likely to be effective against all airborne microbes, including newly emerging virus strains.\n\u201cSo up until now, they\u2019re only really practical when people aren\u2019t around,\u201d say Brenner.\n\u201cThere has been no way of killing viruses in the air in public spaces, and this is an approach that may solve that problem.\u201d\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "People have been looking for something like this for years,\u201d said Dagan Wells of the Nuffield Department of Obstetrics and Gynaecology at Oxford University.\nBut it can happen later or earlier, making it difficult for women who want to develop a career before having babies to know how long to wait.\n\u201cThe possibility of an accurate predictor for menopause is very exciting.\nBut said it would be important to see if the method could also help predict the time when fertility effectively ends.\nThe average difference between the predicted age and the women\u2019s actual age at menopause was a third of a year, and the maximum margin of error was three to four years.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering. The story should have also avoided referring to women who want a career before having babies to know how long to wait. \u00a0Having a career does not preclude having a family, biological or otherwise. ", "answer": 1}, {"article": "Newsday's coverage of the Class of 2019, led by Mariano Rivera and Mike Mussina.\nAt 14, MS-13 was his family.\nHere\u2019s how he got out.\nA hijab, a turban, a beard: What aren\u2019t you seeing?\nFrom a Catholic school uniform to a hijab, LIers talk about their religious clothing.\n", "question": "Does the story commit disease-mongering?", "explanation": "The natural history of Parkinson\u2019s or its variability are not presented", "answer": 0}, {"article": "\"We didn't expect that at all,\" Dackis says.\nIn a small safety study to ensure that modafinil didn't make cocaine worse, some users found the once-a-day pill blocked that high.\nThe prospect of that double-whammy has the National Institutes of Health spending $10.8 million researching modafinil as a potential cocaine treatment.\nHundreds of cocaine users are testing whether that legal pill, called modafinil, could help them kick the addiction, and there's early evidence that it may.\nThe main side effect so far: insomnia, not surprising as modafinil is sold today to help narcolepsy patients fend off that neurologic disease's sudden sleep attacks.\n", "question": "Does the story commit disease-mongering?", "explanation": "No real evidence of disease mongering. The drug is promoted here to treat cocaine addiction and the incidence of this addiction is reported at 1.5 million in the U.S., however only about 250,000 were in substance abuse treatment (Substance Abuse and Mental Health Services Administration).", "answer": 1}, {"article": "\u201cSometimes you don\u2019t get the same result.\nAn MRI can also help determine how aggressive a tumor is, Yu said, and indicates if the tumor extends outside of the prostate and involves other areas \u2014 all information that helps urologists and radiation oncologists determine the best course of treatment.\nAccording to the Center for Cancer Research study, MRI targeted biopsies detect 17 percent fewer low-risk tumors.\nWhen PSA is above 4 nanograms per milliliter of blood, it can be one of the first signs of a prostate tumor.\nWhen caught early, prostate cancer is highly treatable.\n", "question": "Does the news release commit disease-mongering?", "explanation": "While prostate cancer is serious, this news release seems calculated to instill fear. It omits some important facts, such as that PSA levels often fluctuate and can be elevated for reasons that have nothing to do with prostate cancer. In fact, only about 25 percent of men who have a biopsy due to an elevated PSA level actually have prostate cancer, according to\u00a0cancer.gov.\nRelating the story of a patient whose cancer was diagnosed with an MRI after standard biopsies were inconclusive, the news release says other patients who continue to \u201chit a brick wall with negative results from TRUS biopsies yet persistently high PSA levels may not be as fortunate.\u201d A clinician is quoted saying: \u201cIf you do not have this kind of advanced imaging, sometimes a patient runs into a situation when a tumor can\u2019t be found and treated because it\u2019s too late \u2014 it has already metastasized. He ends up diagnosed with cancer only after the tumor has spread to his bone or lymph nodes years later.\u201d\nThe statement, \u201cWhen caught early, prostate cancer is highly treatable,\u201d is also troubling. In fact, prostate cancer does not always need to be treated, and treatment can result in long-term sexual side effects as well as urinary and bowel problems.\nTo avoid disease mongering, the release could have clarified that an elevated PSA test does not always identify cancer. Men can have elevated levels without cancer. Some of those with an elevated PSA who undergo an MRI will have a negative test \u2014 just like a negative biopsy.", "answer": 0}, {"article": "\"It's my job to see that she gets what she needs to protect herself,'\" he says.\nThe vaccine promises to reduce the number of HPV related cervical cancers by more than 70 percent, CBS News correspondent Cynthia Bowers reports.\nThe FDA only approved Gardasil in June and already, there is talk of making the $360 vaccine mandatory for the 2 million American girls who enter the sixth grade every year.\nMillions of Americans have seen the ad blitz for Merck's new drug Gardasil.\nBut some worry that may sends a mixed signal by protecting girls against a sexually transmitted disease while at the same time telling them they shouldn't have sex.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate the annual number of deaths from cervical cancer. The story could have provided more context for these numbers \u2013 for example, how common HPV is and how rare it is for HPV infection to lead to cervical cancer.", "answer": 1}, {"article": "It also said Repatha\u2019s effect on mental function was similar to placebo, likely alleviating concerns that it might impair cognition in some patients.\nBut those who control budgets wanted concrete proof that the drug could actually reduce the risk of heart attacks and death before making it easier for patients to get the medicine.\nNo new safety problems cropped up in the 27,500 patient study called Fourier, Amgen said.\nThe primary goal also included need for a new artery-clearing procedure and hospitalization for angina.\nThe company said Repatha would be well on its way to becoming a $1 billion seller if all prescriptions written had been filled.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story doesn\u2019t appear to be disease mongering. We do wish it had included some statistics on the prevalence of heart disease, which is something the news release did.", "answer": 1}, {"article": "Holick.\nThis device for making vitamin D is ideally suited for patients with fat malabsorption syndromes including inflammatory bowel disease and gastric bypass surgery.\nAbout Vitamin D3 Two forms of vitamin D are important to humans: vitamin D2 produced by plants, yeast and mushrooms, and vitamin D3 produced by skin when exposed to sunlight or the appropriate wavelength of ultraviolet light.\nThe research shows that RayVio's UV LEDs could be used for treating patients that are vitamin D deficient.\nVitamin D deficiency is associated with osteoporosis, rickets and other metabolic bone diseases and is more prevalent in northern and southern latitudes where sunlight is limited for a significant part of the year.\n", "question": "Does the news release commit disease-mongering?", "explanation": "Without stating the source or elaborating further, the release states that 75 percent of teens and adults in the US are vitamin D deficient. However, noted experts have disputed high claims of deficiency as being a misinterpretation of Institute of Medicine nutrition guidelines.\nBeing vitamin D deficient in itself is not a disease. It can lead to a loss of bone density, contributing to osteoporosis and fractures. Severe vitamin D deficiency in the US is rare, and the effects of vitamin D on other conditions need to be investigated further.\nFor these reasons we rate this Not Satisfactory for disease mongering.", "answer": 0}, {"article": "\"We compare the colored glasses to being like a brace or cast but for the brain,\" he says.\n\"Sensitivity to light can be common and impact activities of daily life suggesting that light mitigation might improve quality of life in many of these patients.\nPhotophobia is so common that many neurosurgical intensive care units consider it standard operating procedure to keep lights dimmed in rooms containing TBI patients says Clark.\n\"What is needed is a light mitigation strategy that can be readily employed indoors, which can optimize relief in those who suffer from photophobia, or light sensitivity.\"\nOur goal in this study was to provide medical staff like athletic trainers with a method and means to assess and subsequently provide relief to an athlete who may be experiencing symptoms of photophobia,\" Clark adds.\n", "question": "Does the news release commit disease-mongering?", "explanation": "We did not find any disease mongering in the piece. Concussion and TBI numbers are very tricky because so few concussions are actually captured. TBIs are mostly tracked through ER visits. The CDC puts the TBIs that lead to ER visits at 2.8 million annually. So given that there are likely more mild concussions than true TBIs, this puts the 3.8 million number into conservative territory \u2014 if not well below where it should be.", "answer": 1}, {"article": "Food sources of vitamin E include wheat germ, nuts such as almonds and hazelnuts, vegetable oils such as sunflower and safflower oils, and some green vegetables, such as spinach and broccoli.\nIt is unlikely that people could get too much vitamin E from food.\nWhen Breteler\u2019s team considered a number of other factors \u2014 including participants\u2019 age, education, weight, and smoking and drinking habits \u2014 high vitamin E intake was linked to a one-quarter reduction in dementia risk.\nHowever, the new study followed participants for a longer period than most previous studies on antioxidants and dementia.\nAnd it supports findings from some previous research that dietary vitamin E, in particular, might be related to a lower risk of dementia.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering of dementia in this story.", "answer": 1}, {"article": "In the study, men taking an angiotensin receptor blocker had a 24 percent lower incidence of dementia than those taking other cardiovascular drugs.\n\"You only know for sure when you have done clinical prospective trials.\"\nThe risk was nearly halved for those taking both angiotensin-targeting drugs.\nCaution was urged by Dr. Richard B. Lipton, vice chairman of neurology at Albert Einstein College of Medicine in New York City, who has done work on the genetics of Alzheimer's disease.\nBut there have been a number of observational studies implicating various molecules, including estrogens, in dementia, he said.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no overt disease-mongering of dementia in the story. ", "answer": 1}, {"article": "For the really Type A personality, here's a chance to measure how well you are relaxing. Makers of home biofeedback devices that monitor your heart rhythms say the devices teach you to combat emotional stress. Psychologists and psychiatrists say the gadgets appear to help their stressed-out patients but warn that there isn't yet strong scientific evidence that they work.\n\nBiofeedback has long been used to treat stress in psychologists' offices -- with an expert who leads the patient in relaxing breathing exercises and...", "question": "Does the story commit disease-mongering?", "explanation": "It is not clear from the story what the disease is. Stress is mentioned, but so is depression, asthma, anxiety, insomnia, etc.", "answer": 0}, {"article": "As we cut calories and lose weight, our resting metabolic rate eventually slows and our bodies become less efficient at shedding mass in a process known as adaptive thermogenesis.\nHowever, it\u2019s important not to think of them as cheat days.\nBut, Varady believes it\u2019s probably safe to enjoy a slice of cake or bowl of ice cream during the break.\nWhile frustrating, it\u2019s one of our natural survival mechanisms to prevent potential starvation.\n\"Somehow they\u2019re kind of keeping the body on its toes.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "No mongering; the article did a pretty good job of noting the ups and downs of weight loss schemes.", "answer": 1}, {"article": "Those are also symptoms of a deficiency of B12, a key nutrient needed to make red blood cells and DNA and keep the nervous system working right.\n\nVitamin B12 deficiency is officially considered rare, affecting about 1 in 1,000 Americans, according to a 2005 study. But the incidence...", "question": "Does the story commit disease-mongering?", "explanation": "This story including many laundry lists of symptoms ranging from the commonplace (sluggish) to scary (irreversible neurological problems) without appropriate context as to the incidence of the more serious problems or bothering to discuss that many of the problems described commonly result from problems other than vitamin B12 deficiency.", "answer": 0}, {"article": "In Belgium, engineer and nuclear physicist Yves Jongen is pioneering a new therapy that targets cancers with proton radiation; a therapy that offers precision and minimal side effects.\nWhile proton therapy is a giant step forward, it's not yet the magic bullet that clinicians are looking for.\nAs the fame of the process has started to spread, some people have been taking desperate measures to get treatment.\nOther centers, however, are currently in development.\n\"If you look at leukemia, which is cancer of the blood cells, there is nowhere to shoot -- it's all through the body.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "A story such as this one, that makes only broad, sweeping claims about cancer \u2013 in general \u2013 never provided enough information about any one disease or condition to even warrant a satisfactory or unsatisfactory grade. \u00a0This can only be ruled as Not Applicable.", "answer": 2}, {"article": "The results have not previously been published or presented.\nThere is also a dramatic price difference between the two diagnostic tests.\nThe cost of a C-Tb test is to be determined; however, it is expected to be significantly less than an IGRA.\nIntroduced a decade ago, IGRAs have high specificity, producing few false positives, but require blood samples and complicated lab work, which has limited their widespread use.\nThe new test measures the body's immune response to two TB antigens, EAST-6 and CFP10.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release does not commit disease mongering.", "answer": 1}, {"article": "Another sensor, just approved by the F.D.A.\nMiniMed\u2019s studies show the sensor\u2019s accuracy can be off by as much as 18 percent.\nThe main problem was that the sensor was simply not as accurate as a blood-glucose tester.\nLike the pump, the sensor requires injecting a tiny catheter (less than an inch long) into the midsection of the body, and changing it every three days to avoid infection.\nEven with the help of an expert trainer from MiniMed, I found that injecting the catheter took much more dexterity than injecting one for a pump.\n", "question": "Does the story commit disease-mongering?", "explanation": "The level of monitoring and use of injections as described in this article are beyond what has been tested in randomized controlled trials. ", "answer": 0}, {"article": "\"It's very easy to do, and it's very quick to do.\"\nThere is currently no cure for dementia, though medication can be used to temporarily treat its symptoms.\n\"What we do know is that the blood supply in the brain is incredibly important, and that maintaining a healthy heart and blood pressure is associated with a lower risk of developing dementia,\" said Carol Routledge, Director of Research at Alzheimer's Research UK, who was not involved in the research.\nThe study's findings have been met with cautious optimism by dementia organizations.\nThe test, which analyzes the pulse of blood vessels in the neck, could become part of routine testing for cognitive decline, according to the study by scientists at University College London (UCL), who presented their work Sunday at the American Heart Association's annual scientific conference.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here. However, it is worth noting that the story does make one confusing statement. In a sentence immediately following a paragraph about dementia, the story states that \u201cIn the United States, the condition is the sixth biggest cause of death among all adults.\u201d That\u2019s inaccurate. Alzheimer\u2019s disease, specifically, is the sixth leading cause of death among all adults, according to the CDC. Dementia and Alzheimer\u2019s are lumped together by the UK\u2019s Office for National Statistics, which may have led to the confusion.", "answer": 1}, {"article": "Mpourmpakis and Taylor applied density functional theory (DFT) - a highly accurate computational method used to study the structure and properties of materials - to address how HCA and CA bind to calcium and to calcium oxalate crystals.\n\"HCA shows promise as a potential therapy to prevent kidney stones,\" the researchers wrote.\nJeffrey Rimer, associate professor of chemical engineering at the University of Houston, was lead author of the study, published Aug. 8 in the online edition of Nature.\nThis finding could lead to the first advance in the treatment of calcium oxalate stones in 30 years.\n\"HCA may be preferred as a therapy over CA (potassium citrate).\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release is in line with common estimates when it states that up to 12 percent of men and 7 percent of women are affected by kidney stones, and that the incidence is rising.", "answer": 1}, {"article": "Labovitz also points out that the group of men who had fewer strokes were younger, had lower blood pressure and smoked less than the group more prone to stroke.\nBut the foods we eat are complex and filled with many nutrients, making it tough to prove what is really providing benefits.\nThough the study looks promising, experts say that we can't necessarily give all of the credit to lycopene.\nIf we don't eat enough lycopene-packed foods, experts suspect too many free radicals get left in the body, damaging blood vessels by helping to form fatty deposits.\n\"A diet containing tomatoes... a few times a week would be good for our health.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering of stroke.\u00a0 However, the description of free radicals did sound a little alarming.\u00a0 They are natural byproducts of our biochemical processes.", "answer": 1}, {"article": "For instance, it only became apparent after about five years for esophageal, pancreatic, brain, and lung cancer; about 10 years for stomach and colorectal cancer; and about 15 years for prostate cancer.\nThe study is by Peter Rothwell, MD, PhD, FRCP, of John Radcliffe Hospital in Oxford, England, and colleagues, and has been published online by the journal the Lancet.\nThe investigation also showed that the benefits of taking aspirin increased over time.\nThe study looked at eight trials examining the effects of a daily dose of aspirin on preventing heart attacks involving 25,570 patients, 674 of whom died from cancer.\nParticipants were also followed up after 20 years, by which point 1,634 of the original participants had died as a direct result of cancer.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease-mongering.", "answer": 1}, {"article": "The United States recommends that men and women over age 31 eat 420 and 320 milligrams of magnesium daily, respectively.\n\"It's again the diet per se, not any one individual component of the diet.\"\n\u201cIt\u2019s a diet that\u2019s rich in fruits, vegetables and grains.\nAbout 6,500 of them, or three percent, had a stroke in the time they were followed.\nMost of the studies allowed the researchers to rule out other factors, such as family history.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "N-acetylcysteine reduced PTSD symptoms, cravings, and depression in veterans with PTSD and substance use disorder in a randomized controlled pilot trial conducted at the Medical University of South Carolina and the Ralph H. Johnson VA Medical Center\n\nN-acetylcysteine, when combined with group cognitive behavioral therapy (CBT), reduced symptoms of posttraumatic stress disorder (PTSD), cravings, and depression significantly more than CBT alone in veterans with co-occurring PTSD and substance use disorder, a particularly difficult-to-treat population, according to the findings of a randomized controlled pilot trial conducted by researchers at the Medical University of South Carolina (MUSC) and the Ralph H. Johnson VA Medical Center.\nThis finding could also be due to the relatively limited number of participants or to the chronic nature of the participants' PTSD.\nThe National Center for PTSD estimates that seven to eight percent of Americans will have PTSD at some point in their life.\nBecause evidence suggests that SUDs and PTSD share overlapping neurobiological pathways, Sudie E. Back, Ph.D., lead author on the article, hypothesized that NAC treatment with CBT would be a novel approach to treat co-occurring PTSD and SUD.\n\"People who are prone to psychiatric disorders are also prone to addiction.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no obvious disease-mongering here. However, when the release notes that 7-8 percent of Americans have experienced PTSD at some point in their lives it could have been noted that the PTSD experienced by military veterans \u2014 leaving them \u2018difficult-to-treat\u2019 \u2014 is in a different category than what civilians might experience.", "answer": 1}, {"article": "\u201cIt\u2019s time for her to be a kid again and get her childhood back,\u201d Mr. Whitehead said.\nDespite the mixed results, cancer experts not involved with the research say it has tremendous promise, because even in this early phase of testing it has worked in seemingly hopeless cases.\nHerv\u00e9 Hoppenot, the president of Novartis Oncology, called the research \u201cfantastic\u201d and said it had the potential \u2014 if the early results held up \u2014 to revolutionize the treatment of leukemia and related blood cancers.\nOne patient had a remission after being treated only twice, and even then the reaction was so delayed that it took the researchers by surprise.\nShe woke up a week later, on May 2, the day she turned 7; the intensive-care staff sang\n\nSince then, the research team has used the same drug, tocilizumab, in several other patients.\n", "question": "Does the story commit disease-mongering?", "explanation": "While certainly a terrible disease, acute lymphoblastic leukemia is\u00a0a treatable cancer. The 5-year survival rate\u00a0(percentage of patients who live\u00a0at least 5 years after their cancer is diagnosed), is more than 85%, according to the American Cancer Society, and many patients who survive that long are considered cured because relapse is rare. This story focused on one of the worst case scenarios, and didn\u2019t provide readers with this larger perspective.\nThe competing Philadelphia Inquirer story at least briefly referenced the 85% estimate.", "answer": 0}, {"article": "Accumulations of neurotoxic beta-amyloid protein can be detected with positron emission tomography, or PET scans, and analysis of cerebrospinal fluid, but these are invasive, inconvenient and costly, making them impractical for routine screening and follow-up evaluation.\nShe is the senior leading author of an article in JCI Insight published online Aug. 17.\nClinical trials were approved by Quorum Review, Seattle, Washington, (IRB00003226) and the U.S. Department of Health and Human Services (FWA00019841).\nThe article provides new insights into the disease's manifestations in the retina and information on the optical imaging system.\nKoronyo-Hamaoui, Verdooner, Koronyo and Black are founding members of NeuroVision.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in the release.", "answer": 1}, {"article": "\u201cIt could potentially do so much more.\nOutdoor air pollution is a global health crisis that kills over 3 million people a year and it has long been linked to lung and heart disease and strokes.\nBilstein said the inhaler could be useful around the world, as particulate air pollution is not just a European problem: \u201cEspecially in Asia \u2013 China in particular \u2013 the demand for such a product is even higher.\nVehicles are a key contributor to air pollution but, a year after the VW emissions scandal broke, most new diesel cars still emit far more toxic nitrogen oxides on the road than the official lab-based limit.\nBut research is also uncovering new impacts on health, including degenerative brain diseases such as Alzheimer\u2019s, mental illness and, this week, diabetes.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is a suggestion that all of us who live in cosmopolitan areas where particulate pollution is a problem will need to start and end our day with an ectoine inhaler or risk type 2 diabetes, Alzheimer\u2019s disease, COPD and a host of other maladies.\nAlso, the article should be mindful of statements such as the ones below, which may unintentionally incite fear in the public.\n\u201cOutdoor air pollution is a global health crisis that kills over 3 million people a year\u2026\u201d\n\u201cIn the UK, at least 40,000 people a year die prematurely from air pollution, with a cross-party committee of MPs calling it a \u201cpublic health emergency.\u201d\nThese types of statistics are, first of all, hard to wrap one\u2019s mind around. Overuse of them has numbed people to their impact and effect.", "answer": 0}, {"article": "\u201cIf people paid more attention to guidelines, more people would be on the drug,\u201d Dr. Jacobson said.\nLater studies have continued to yield positive results, although some scientists say there are still gaps in knowledge.\nApproval from the agency for the use of the drug in heart disease is not expected soon.\nIt seems natural for Italy to be at the forefront of the fish oil trend and home to the largest clinical trials.\nThis meant that, despite impressive results, the trial did not meet the F.D.A.\u2019s standards for approval.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no evidence of disease-mongering. ", "answer": 1}, {"article": "\"By actually (measuring) the brain network activity directly, you can look at really what is the functional health of the brain,\" he said.\n(CNN) A saliva test may someday be able to diagnose a concussion and predict how long symptoms last, according to a study published Monday in the JAMA Pediatrics.\n'Way too early to know'\n\nHowever, the editorial authors, Dr. William P. Meehan III of Micheli Center for Sports Injury Prevention at Boston Children's Hospital in Massachusetts and Dr. Rebekah Mannix of Brain Injury Center at Boston Children's Hospital, noted that \"the relatively small sample size in this study requires larger-scale studies to determine the reliability\" of the results.\nStill, \"the findings are promising, representing potential biomarkers for the diagnosis, recovery, and prognostic assessment of a sport-related concussion.\"\nMicroRNA expression was measured in saliva spit into a cup by the patients, who had been injured mostly in sports or car accidents, when they arrived at Penn State Hershey Medical Center for an evaluation.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not commit disease-mongering. However, one paragraph discussing data from the Centers for Disease Control could be viewed as conflating concussions with all traumatic brain injuries (TBIs). The story notes that CDC data showed 2.8 million TBI-related visits to the emergency room, hospitalizations and deaths in the United States in 2013. Following this figure immediately is a reference to two-thirds of concussions occurring in children and adolescents; the structure thus suggests that all 2.8 million TBIs were concussions.", "answer": 1}, {"article": "Asthma on the Rise in U.S.\nThere is no cure, but most people can control their symptoms, reduce the severity of their disease, and prevent asthma attacks by avoiding asthma triggers and correctly using prescribed medicines, such as steroid inhalers, the CDC says.\nThe number of people in the U.S. with asthma is growing.\nNorth American allergy experts tell WebMD that although they find the preliminary findings fascinating, further study is needed before they would recommend the herbs.\nSymptoms completely disappeared in 94% of patients taking kampo herbs after an average of 16 days, Shimoide says.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering at play.\u00a0 The story reported:\nThe number of people in the U.S. with asthma is growing. One in 12 people had asthma in 2009, compared with 1 in 14 in 2001, according to the CDC.\nThere is no cure, but most people can control their symptoms, reduce the severity of their disease, and prevent asthma attacks by avoiding asthma triggers and correctly using prescribed medicines, such as steroid inhalers, the CDC says.", "answer": 1}, {"article": "Related: New Test Detects Heart Disease Risk, Especially for Black Women\n\nIt\u2019s not just the fat cells that lead to heart disease, the No.\n\u201cTreatments that are known to reduce the risk of heart attacks, such as statin drugs, reduce inflammation much more than any detectable reduction in coronary artery narrowing,\u201d said Oxford\u2019s Keith Channon, who also worked on the study.\nIt\u2019s inflammation, also.\n\u201cBut until now, there's been no way to detect inflammation in the coronary arteries.\u201d\n\nRelated: Half of People Who Have Heart Attacks Don\u2019t Even Know It\n\nDoctors run many different tests to assess someone\u2019s risk of heart disease.\n\u201cOur new method also allows detection of those small but inflamed artherosclerotic plaques in our heart arteries that are prone to rupture, therefore are about to cause a heart attack,\u201d Antoniades told reporters in a telephone briefing.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here. The story stated that \u201cabout 750,000 Americans have a heart attack every year.\u201d", "answer": 1}, {"article": "\"So, yes, one of the limitations of this kind of study is always the question of its generalizability to other populations,\" he cautioned.\nThe 458 male participants in the original study had been between the ages of 30 and 59 at enrollment, and all had a history of heart disease, with most having survived a heart attack.\nRamsden acknowledged that the Sydney study had been narrowly focused on a specific group of people: middle-aged men with a history of heart disease, who were asked to consume linoleic acid in quantities far exceeding both AHA guidelines and the dietary habits of most Americans.\nBut an updated look at the study indicates that heart disease patients who follow this advice may actually increase their risk for death.\nBy newly crunching all the original data the NIH team found that, compared to the no-dietary-change group, the linoleic acid group faced a higher risk of death, from both heart disease specifically as well as from all causes overall.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering of heart disease. The story is clear that the study involved middle-aged men with a history of heart disease and might not apply to other groups.", "answer": 1}, {"article": "\"Wow!\"\nThe improvement at six months was still present almost a year after the study's start.\nNow there are some promising results from a study in 161 people with a specific genetic mutation that affects about four percent of cystic fibrosis patients.\nBut these results, even with plenty of caveats, suggest the drug is on the right track.\nAnd the drug hasn't been submitted for review by the Food and Drug Administration, though Vertex expects to do that later this year.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here. It was clear that this was a study in people with a specific genetic mutation that affects only about four percent of CF patients.", "answer": 1}, {"article": "JACC is ranked No.\nThe study and editorial are part of a comprehensive Population Health Promotion issue of the Journal of the American College of Cardiology focusing on issues that broadly impact public health and the prevention of cardiovascular disease and related conditions.\nThe largest positive changes in body fat were seen in the 3-year-old group that received three years of interventions.\nProgram.\"\nThe mission of the College is to transform cardiovascular care and to improve heart health.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in this release.", "answer": 1}, {"article": "DOI: 10.1001/jamacardio.2016.4828\n\nCONTACT: For more information or to schedule an interview, please contact the NHLBI Office of Science Policy, Engagement, Education, and Communications at 301-496-5449 or nhlbi_news@nhlbi.nih.gov (link sends e-mail)\n\nPart of the National Institutes of Health, the National Heart, Lung, and Blood Institute (NHLBI) plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders.\nNHLBI press releases and other materials are available online at http://www.\nWHO: Jerome Fleg, MD and Yves Rosenberg, MD, M.P.H., Division of Cardiovascular Sciences, NHLBI, NIH, are available to comment on the findings and implications of this research.\nThe study, funded by the National Heart, Lung, and Blood Institute (NHLBI), appears in the December 28 issue of JAMA Cardiology.\nFor more information about NIH and its programs, visit http://www.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in this release. But there\u2019s very little context about the disease either.", "answer": 2}, {"article": "New Jersey and Ohio were the first to participate statewide in the program.\nThe boxes are a new idea for many Americans.\nPeterson\u2019s daughter, Ariabella, just turned 3 months old.\nThe boxes aren\u2019t the only option for safe sleeping, of course, but health officials say they\u2019re a useful part of a broader safe-sleep education program.\nThe for-profit company also operates in Canada, Ireland and the United Kingdom.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering.", "answer": 1}, {"article": "No serious adverse events were reported.\nNovartis believes the medicine could be filed for regulatory approval in around 2019.\nLarger and longer studies are now needed to prove that the twice-daily pill can also reduce severe asthma attacks, known as exacerbations.\nPills for asthma used to be standard treatment 40 or 50 years ago, but those older products were often associated with worrying side effects.\nLONDON (Reuters) - The first new asthma pill in decades has produced promising results in a small clinical trial, potentially paving the way for another treatment option for patients by the end of the decade.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease-mongering.", "answer": 1}, {"article": "The page may no longer exist or may have moved to another web address. Try again to locate what you want by choosing a section from the navigation menu at left, viewing our Site Map or using the search box below.", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering.", "answer": 1}, {"article": "Transcendental meditation involves shutting out the outside world and focusing thoughts inward, or resting while remaining alert.\nMORE: Losing Focus?\nMost doctors say meditation can\u2019t hurt you, but now there\u2019s reassuring evidence that it may help you as well when it comes to warding off disease.\nMORE: Mind Over Matter: Can Zen Meditation Help You Forget About Pain?\nMost doctors say meditation can't hurt you, but now there's reassuring evidence that it may help you as well when it comes to warding off disease.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering.", "answer": 1}, {"article": "Of those, 2,148 had taken lithium, 1,670 had used valproate, 1,477 had been on olanzapine and 1,376 had taken quetiapine.\nBut as with all areas of mental health there is still more research to be done.\nThere should be more sensible use of it.\u201d\n\nStephen Buckley, head of information at the charity Mind, said: \u201cWe welcome research which adds to our understanding of treatments and medications for people experiencing mental health problems, including bipolar disorder.\n\u201cI think that many patients are missing out quite commonly on the best available treatment.\nPeople rightly have suspicions about it.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no evidence of disease mongering. Given the seriousness of the disorder and its prevalence, we would have liked to have seen read more on how many people it affects.", "answer": 1}, {"article": "Doctor Challenges Cause Of MS And Treatment\n\nOne day 7 years ago, after a long walk with his dog along the Hudson River in Manhattan, Marc Stecker noticed he was limping.\nZamboni himself says that even if it turns out he's wrong, coming to a greater understanding of the disease would be the big reward \u2014 both for him and thousands of MS patients.\nStecker says if he had it to do over again, he would have waited for more research.\nStudying how the vascular system is involved in neurologic disease is an entirely new concept, Zivadinov says.\nRobert Zivadinov of the Buffalo Neuroimaging Analysis Center in New York says that not only is the procedure unsafe and costly to many patients, it is impeding necessary research.\n", "question": "Does the story commit disease-mongering?", "explanation": "Although there was no overt disease-mongering, the story focuses exclusively on the story of a patient who had an aggressive case of the disease. MS can manifest itself in a variety of different ways, and his experience is not representative of patients\u00a0with mild and slowly progressing MS. \u00a0Also, not everyone with MS has the vascular abnormalities discussed in this story, and so would presumably not benefit from this procedure. Finally, the story should have explained that MS is a condition characterized by flare-ups\u00a0that often get better by themselves, so it\u2019s hard to tell if\u00a0\u201cmiraculous\u201d recoveries are attributable to\u00a0the surgery or are\u00a0just the natural course of the disease for these patients.\u00a0A bit more context on these issues would have been helpful, but\u00a0we don\u2019t think the story deserved to be flagged for not including it.", "answer": 1}, {"article": "\"It's kind of amazing that something so simple could be an answer,\" Paul said.\nThe study comes at a time when parents are on the lookout for new ways to give sick children relief.\nHoney also beat out no treatment at all.\nThe study was paid for by the National Honey Board, an industry-funded agency of the U.S. Department of Agriculture.\nUnder the provisions of the grant, the group was not involved in the study or the published results, Paul said.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate the prevalence of common colds.", "answer": 1}, {"article": "This increase in less-invasive biopsies went along with a decrease in the number of more-invasive biopsies and through-the-skin biopsies where no imaging was used, the researchers found.\nThe report is published online and in the September print edition of Radiology.\nIn addition, image-guided biopsies are more accurate, Quencer said.\nI doubt there is any variation to this in any major medical center.\"\nTUESDAY, Aug. 17, 2010 (HealthDay News) -- Less invasive biopsies done with the help of imaging to guide the needle now make up the majority of biopsies being done, a new study finds.\n", "question": "Does the story commit disease-mongering?", "explanation": "Not applicable because no diseases were discussed in any detail. ", "answer": 2}, {"article": "\"It's just that the guidelines don't clearly let you use the tests from that one blood sample to make the initial diabetes diagnosis,\" she explained.\nCurrently, it's recommended that a blood test focused on elevated fasting levels of blood sugar (glucose) or a blood component called glycated hemoglobin (HbA1c) be confirmed with a second blood test at a follow-up visit.\nAccording to Bernstein, if only one diagnostic test were needed, \"this would mean that a follow-up visit would be a look at the treatment benefits -- rather than a confirmation of an abnormal glucose.\"\nThe American Diabetes Association has more on type 2 diabetes.\nDiabetes is treatable, but about 3 million Americans with the disease don't know they have it.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering, but the story would have been stronger with information about who should be screened. For example, the U.S. Preventive Services Task Force recommends checking for abnormal blood glucose as part of cardiovascular risk assessment in adults who are overweight and between 40 and 70 years old, and referring those with abnormal levels to intensive behavioral counseling.", "answer": 1}, {"article": "The second study, published in 2013, had a similar set up \u2014 37 people complaining of gastrointestinal problems, randomized into high-gluten, low-gluten and no-gluten groups.\nHow many people?\nThey were run by the same team.\nSomewhere in that gap, a diet fad is thriving.\nBut how many people really are sensitive?\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering here.", "answer": 1}, {"article": "Women are also more likely to experience a condition known as left bundle branch block, a pattern of disorganized electrical impulses that responds well when the left side of the heart is treated with a pacemaker.\n\u201cWe think this is the first (study) to show this.\u201d\n\nMoss said women have often been overlooked in studies of heart disease, which until recently were dominated by men.\n\u201cOur finding was unexpected, but extremely important because this is the only heart treatment that is clearly better in women than men,\u201d Dr. Arthur Moss of the University of Rochester Medical Center, whose study appears in the Journal of the American College of Cardiology, said in a statement.\nIn the latest study, Moss and colleagues explore how much better women did, and why.\nIn the MADIT-CRT trial, women were more likely to suffer heart failure caused by a viral infection of the heart, whereas in men, the condition is more often caused by blocked heart arteries, Moss said.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story ended with disease mongering about the 42 million American women \u2018living with heart disease\u2019 in a story about heart failure, which, while it may fall under the rubric of heart disease, is only a subset of the vast 42 million. \u00a0The story then went on to share that \u2018It\u2019 is the \u2018leading killer of women\u2019. Why not simply provide heart failure stats, and heart failure stats by gender?", "answer": 0}, {"article": "Separate strands of material become stronger when they link up.\nThey demonstrate it in this video.\nThere are hundreds of skin products that do this now, but this one sticks better and doesn\u2019t pucker the skin, the team reports.\n\u201cCreating a material that behaves like skin is very difficult,\u201d added Dr. Barbara Gilchrest, a dermatologist at the Massachusetts General Hospital who worked on the study.\nIt lasted for 16 hours before it started peeling off, and smoothed out the eye bags that become so common as people age, they wrote.\n", "question": "Does the story commit disease-mongering?", "explanation": "Given the tone of the piece\u2013lots of medical language and interviews with researchers\u2013and that it appeared in the NBC\u2019s\u00a0Health section, we feel this story disease-mongers a normal life event (aging).", "answer": 0}, {"article": "Severely premature babies are more likely to live if they receive intensive-care treatments rather than palliative care to keep them comfortable, according to a U.S. government-funded study published Thursday.\n\nWhether babies born at the extreme edge of viability, generally considered to be 22, 23 or 24 weeks of gestation, should be aggressively medically treated is a controversial issue among pediatric experts. These infants often don\u2019t survive and, even if they do, many have substantial long-term health problems.", "question": "Does the story commit disease-mongering?", "explanation": "The piece does not engage in disease mongering.", "answer": 1}, {"article": "Although tenecteplase appears to be more effective for stroke patients, it's not approved for that use in the United States, according to Dr. Rohan Arora, director of stroke at Long Island Jewish Hospital in Forest Hills, N.Y.\n\"It is likely to change stroke treatment guidelines and clinical practice.\"\n\"One reason is it's cheaper than alteplase.\"\n\"Tenecteplase is being widely used in developing countries, such as India,\" he said.\nIn this study, patients were given the drugs within 4.5 hours after the onset of a stroke, Campbell said.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering here.", "answer": 1}, {"article": "A patient sits in the chair while a magnetic pulse emitter transmits energy from a levered arm \u2014 a process similar to undergoing dental X-rays.\n\"But I've been working on that.\"\nBut TMS is expensive.\nYou've got less side effects than taking a medicine.\"\nThe NeuroStar system resembles a dentist's chair.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here", "answer": 1}, {"article": "\"It seems EPA and DHA are more effective at this.\nHER-2 affects 25per cent of women and has a poor prognosis.\n\"It's known that EPA and DHA can inhibit breast tumour growth, but no one has looked directly at how effective these omega-3s are compared to ALA.\"\n\nMa found overall exposure to marine-based omega-3s reduced the size of the tumours by 60 to 70 per cent and the number of tumours by 30 per cent.\nPublished in the Journal of Nutritional Biochemistry, the study involved feeding the different types of omega-3s to mice with a highly aggressive form of human breast cancer called HER-2.\nThe next step is to investigate the effects of omega-3s on other forms of breast cancer.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release states that the HER-2 form of breast cancer \u201caffects 25 percent of women.\u201d That number seems over-inflated according to other sources.\nThe Mayo Clinic website states \u201cin about 1 of every 5 breast cancers, the cancer cells have a gene mutation that makes an excess of the HER2 protein.\u201d And Cancer Investigation journal put the number of women with HER-2 positive at 19% for women under 49 years and 15% for those over 50 years old.", "answer": 0}, {"article": "While smoking is a public health scourge, the nicotine in cigarettes may have some promise in treating another growing problem, mild cognitive impairment (MCI), which can be a precursor to Alzheimer\u2019s disease or other forms of dementia.\nHowever, when clinical experts rated overall general change in the patients, they did not see a significant difference between the two groups.\nThe study was led by Dr. Paul Newhouse of Vanderbilt University and published in Neurology.\nIntriguingly, it appeared to be more effective among people with two copies of the APOE4 gene, a genetic combination that increases risk for Alzheimer\u2019s by a factor of 20 or higher.\nMORE: Is Nicotine a \u2018Gateway\u2019 to Cocaine Addiction (and Cancer)?\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not resort to disease-mongering.\u00a0 Like the MSNBC story, though, it could have more clearly distinguished between mild cognitive impairment and forgetfulness.", "answer": 1}, {"article": "Source: Australian Bureau of Statistics, 2016, National Health Survey: First results, 2014-15, ABS cat.\n\u201cThis study shows that the new MedDairy works better than a generic low-fat diet, ensuring better health outcomes for people at risk of cardiovascular disease.\u201d\n\nImportantly, the MedDairy diet also meets additional calcium requirements recommended by Australia\u2019s national health bodies.\n\u201cThis study delivers healthier options for Australians by tailoring the nutrients in the MedDiet to meet the needs of a non-Mediterranean population.\nSimilarly, the Mediterranean diet (MedDiet) has been shown to deliver significant health benefits.\n\u201cThe new MedDairy diet allows for three to four servings with dairy, which means Australians can more sustainably meet their recommended daily nutrient intakes while also maintaining the significant health benefits offered through the MedDiet.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no evidence of disease mongering in this release. The release provides useful context on the prevalence of cardiovascular disease in Australia and globally.", "answer": 1}, {"article": "\u201cMore often than not, it\u2019s not clear-cut which way to go,\u201d explained Barry Rosenstein, professor of radiation oncology at Mt.\nWhile there has been greater success in treating cancer, survivors may live many years with side effects after treatment.\nWhile some risk factors are well-known -- including age, diabetes and poor cardiovascular health -- whether a man suffers harsh side-effects is often chalked up to random luck.\n\u2022 Radiation may up breast cancer risk in some women\nKnowing a man\u2019s susceptibility to fallout from radiation may steer a doctor toward surgery instead of other potentially damaging therapy.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering. Prostate cancer is the most frequently diagnosed cancer, most men are diagnosed at an early stage and subsequently undergo active treatments\u2013which carry substantial risks for complications. \u00a0However, the article could have cited estimates for the risk of erectile dysfunction following treatments.", "answer": 1}, {"article": "We will use less disruptive sutures in our next clinical study, and this should correct this problem.\"\nCurrently, some cornea patients get transplanted corneas from donors who have died.\nAn estimated 5 million people in the world have an eye disease called trachoma that affects the cornea, and another 1.5 million to 2 million are thought to have developed cornea-related blindness through other diseases or trauma.\nGriffith said a German study recently found that donated corneas cost about $2,500.\nFor more than a century, doctors have considered transplantation of corneal tissue from deceased donors to be the best treatment, the study authors wrote.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story avoids disease mongering and actually presents a more conservative estimate of the number of people affected by corneal disorders. An estimated 5 million people in the world have an eye disease called trachoma that affects the cornea, and another 1.5 million to 2 million are thought to have developed cornea-related blindness through other diseases or trauma.", "answer": 1}, {"article": "Scientists have used a form of stem-cell therapy to improve survival rates for the most severely sick lupus patients, a group that usually has no remaining treatment options.\n\nLupus is an autoimmune disease that attacks an individual's own organs, causing symptoms that range from swollen joints and skin rashes to severe damage to kidneys, lungs and other parts of the body.", "question": "Does the story commit disease-mongering?", "explanation": "Presented an estimate for the number \nof people affected by lupus (1.5 million in the U.S.) as well as an estimate (5-10%) for the proportion of patients who did \nnot respond to standard treatment.", "answer": 1}, {"article": "Where did this Ron DeSantis come from? Florida\u0092s governor surprises everyone but himself.\n\nA month into his term, Gov. Ron DeSantis has shattered assumptions that he would govern exclusively from the right. He has drawn unexpected praise from Republicans and Democrats.", "question": "Does the story commit disease-mongering?", "explanation": "This story engaged in disease mongering. \u00a0Cirrhosis of the liver is a serious condition and though its incidence appears to be on the rise in seriously obese children, liver disease should not be the top concern for parents of children who are overweight or simply obese. \u00a0The story made it sound as though all children with cirrhosis will require a liver transplant.\nIt presented data that exaggerate the prevalence and severity of the condition in children and provoke fear in the reader. The article says that 2 to 5 percent of kids over age 5 may have NASH, but then says as many\u00a0as 10 percent of children and half of obese children have it. \"It\" being a very mild and early form of the condition,\u00a0that may\u00a0or may not lead to long-term problems. Cirrhosis and the need for liver transplant remain very rare conditions in children. ", "answer": 0}, {"article": "JACC is ranked No.\nThey also looked a several early indicators of heart disease.\nThe mission of the College is to transform cardiovascular care and to improve heart health.\nThe latest research and clinical practice updates in cardiology are at your fingertips with the JACC Journals app for iPhone/iPad and Android.\nThe ACC leads in the formation of health policy, standards and guidelines.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release is good on this front. It does not commit disease-mongering of\u00a0cardiovascular diseases.", "answer": 1}, {"article": "\"I feel like I can accomplish what I want to accomplish.\nIt's unclear how many patients have had to stop or chosen to stop treatment for depression due to side effects.\nAccording to a study conducted by the Mayo Clinic that looked at one genetic test similar to many used in hospitals \u2014 GeneSight Psychotropic \u2014 symptoms of depression were reduced by 70 percent compared to treatments prescribed without genetic testing.\nWhile the results are striking, this technology is not a guarantee of complete resolution of depressive symptoms or medication side effects.\nThe Genefolio test confirmed gene variants within Ellis\u2019 DNA that made her more susceptible to certain side effects with newer classes of medications, so Stanley prescribed an older class of antidepressant and experimented with a lower dose.\n", "question": "Does the story commit disease-mongering?", "explanation": "The single patient profiled who took 23 different combinations is not representative of typical person with depression.\u00a0Also, the story said that \u201cmany\u201d people with depression experience severe side effects, but offers no data to back up such a claim.", "answer": 0}, {"article": "She is hardly alone in her suffering.\nBut the pain is far more controlled, and I can function much better at my current level of discomfort.\u201d\n\nAs the human and financial costs of the opioid crisis rise, spinal stimulation may become more popular, even though it\u2019s expensive.\nIn an article on Popular Science\u2019s website, Jay writes about her experience with pain and the next-generation way she\u2019s finding relief.\nAccording to the National Center for Health Statistics, an estimated 25.3 million Americans, or 11.2 percent of U.S. adults, experience chronic pain.\nShe also describes her path to spinal stimulation, how the device works with the body to short-circuit pain, and the many roadblocks to relief that patients face.\n", "question": "Does the story commit disease-mongering?", "explanation": "The statement that \u201can estimated 25.3 million Americans, or 11.2 percent of U.S. adults, experience chronic pain\u201d suggests that there are millions of Americans who could be lifted out debilitating misery with this technology. The story should have attempted to give an accurate picture of how many people could actually benefit.\u00a0\n The implication is that this procedure may be appropriate for many patients with chronic pain. Given that there is very little evidence to support this treatment as safe and effective, the thought of spending billions to place them in the millions of individuals mentioned is frankly scary.", "answer": 0}, {"article": "In nonsurgical spinal decompression, a patient is placed on a special type of table with harnesses on the pelvis and rib cage.\nI would say a quarter of my patients fall asleep.\u201d\n\nThe decompression therapy is used to treat herniated discs, ruptured discs, sciatica, bulging discs, degenerative discs, posterior facet syndrome and spinal stenosis/arthritis.\nThe new beds, Fuh said, are much different than similar beds made 20 years ago where patients would lie on their stomachs, put a strap around their pelvis and \u201chold onto handle bars for dear life.\u201d\n\n\u201cThe table now, you just lay on your back, and the machine does all of the work.\nDr. Bernard Fuh, director and owner of Advanced Spinal Health in Tulsa, said spinal disc decompression therapy has repaired ruptured discs, eliminated back pain and caused some patients at his center to \u201cgrow\u201d a few inches.\nUntil now, the main options for treatment were surgeries that could involve cutting away bone and placing rods, and rising doses of painkilling medicines that often lead to addiction.\n", "question": "Does the story commit disease-mongering?", "explanation": "By describing a patient who \u201ccame crawling into my practice,\u201d the story crosses the line into disease mongering. This case represents an extreme example of herniated disc. Many patients are not as bothered by symptoms. The story also starts out by saying that this is a new treatment for herniated discs, but later claims that it can be used to treat a wide variety of back pain conditions. The story also does not explain that this treatment should not be used in people who have had back pain for less than a few months, for whom exercise and time would be the best course of treatment.", "answer": 0}, {"article": "LONDON (Reuters) - A non-surgical treatment for low-risk prostate cancer in which doctors inject a light-sensitive drug derived from deep-sea bacteria into a patient\u2019s bloodstream was shown in a trial to kill cancer cells without destroying healthy tissue.\n\u201cThese results are excellent news for men with early localized prostate cancer, offering a treatment that can kill cancer without removing or destroying the prostate,\u201d said Mark Emberton, a University College London consultant urologist who led the trial.\nResults of a trial in 413 patients showed that the drug, which is activated with a laser to destroy tumor tissue in the prostate, was so effective that half the patients went into remission, compared with 13.5 percent in a control group.\n\u201cThis is truly a huge leap forward.\u201d\n\nThe treatment, called vascular-targeted photodynamic therapy or VTP, was developed by scientists at the Weizmann Institute of Science in Israel in collaboration with the privately-owned STEBA Biotech.\nWhile radical therapy causes lifelong erectile problems and incontinence, VTP only caused short-term urinary and erectile problems which resolved within three months, the researchers said.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story shares the flaws of the news release it\u2019s based upon.\nIt says that prostate removal causes lifelong erectile problems, but this is not always the case. Nerve-sparing procedures can preserve potency for a substantial proportion of patients.\nIn addition, active surveillance is described as monitoring and treating only \u201cwhen\u201d the cancer becomes more severe. The correct phrasing would be \u201cif and when\u201d the cancer progresses, because many of these cancers will not progress.\nThe phrasing \u201ckills cancer\u201d in the headline is also questionable, as it sends a false message that low-risk prostate cancer needs to be eradicated. In fact, most men with small, isolated prostate cancers can live for years without treatment.", "answer": 0}, {"article": "COLUMBIA, Mo.\n\"Although this condition usually occurs in men older than 50 with a family history of the disease, anyone can have an abdominal aortic aneurysm,\" said Todd Vogel, associate professor and chief of the Division of Vascular Surgery at the MU School of Medicine, and lead author of the study.\nThe bottom line is that patients who used statins were more likely to survive during and after an elective endovascular procedure.\"\n\"The patients who took statins and had endovascular repairs had a 26 percent decrease in mortality up to one year after surgery.\n\"However, further research is needed to assess the benefits of using statins before surgical repair of other types of aneurysms.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "We rarely ding stories on this criterion, but this one struck us wrong because of the mismatch between the first few sentences and what the science found. It says, \u201cRupture of an abdominal aortic aneurysm is one of the most dramatic medical emergencies a person can face. It usually strikes without warning, killing approximately 50 percent of those who experience it before they reach a hospital. Of those who do get to a health facility alive, only about 50 percent survive.\u201d Are you scared? Well, you probably are hoping that these researchers have found a way to save you from dying unexpectedly before you get to the hospital. But they haven\u2019t. Nor have they found something that is going to guarantee that you won\u2019t die once you reach the hospital, not if the aorta is already ruptured, although we must note that the release is confusing on this point because the provenance of the survival statistics is unclear. What\u2019s also confusing is that the release is conflating an enlarged aorta \u2014 which is a serious but manageable condition known as an\u00a0aortic aneurysm \u2014 with a ruptured aorta, which is what leads to people bleeding to death at high rates. The statins might be helpful for people who have an aneurysm that\u2019s surgically repaired; they do nothing in the event of a rupture. In all, the picture painted is far grimmer than the actual context necessary for this release, which is that if people have an aortic aneurysm they might benefit from statins.", "answer": 0}, {"article": "Texas rep expects Trump to make case for a border wall at State of the Union\n\n\"We're going to keep working to secure the border, and not blink until we either get it done or the voters get to speak in 2020\"", "question": "Does the story commit disease-mongering?", "explanation": "No obvious disease mongering. The story accurately represents the prevalence and seriousness of breast cancer.", "answer": 1}, {"article": "Foxman B, Barlow R, D'Arcy H, Gillespie B and Sobel JD.\n\"While recommendations for dosage and duration of treatment require further study, the efficacy of the medicinal properties of cranberry products has been well-established.\"\nThe review explains that the medicinal properties of cranberries may be attributed to their unique polyphenol, proanthocyanidins - or PACs, for short.\nIt is estimated that one third of women in the United States will get a UTI by the age of 24.2\n\n\"Findings like this,\" adds Dr. Luis, \"give practitioners a viable, inexpensive, non-antibiotic option to help patients reduce the recurrence of an uncomfortable and potentially debilitating infection.\"\nFor more information about the Cranberry Institute, along with the health benefits of cranberries and current scientific research, visit http://www.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here. The release refers to a UTI as a \u201cpotentially debilitating infection,\u201d but given that UTIs can lead to kidney damage or sepsis, that\u2019s not inaccurate.", "answer": 1}, {"article": "A popular new type of prenatal test intended to find genetic flaws in a fetus can in rare cases also reveal previously undiagnosed cancer in the mother.\n\nThe unexpected finding emerged in a study involving eight women who initially had abnormal results from the prenatal blood test, but for whom a subsequent assessment showed their babies were normal. When the mothers\u2019 DNA was reanalyzed, researchers said, the anomalies were linked to cancer in each of the women.", "question": "Does the story commit disease-mongering?", "explanation": "The story never\u00a0suggests that fetal chromosomal abnormalities or maternal cancers uncovered by the blood tests are a major threat. Unlike the CBS story, WSJ notes that the cases identified in the study were culled from more than 100,000 samples and that such findings are \u201crare.\u201d The tone of the story is cautious and it quotes experts who call for further studies and conversations about the current and potential use of diagnostic prenatal blood testing.", "answer": 1}, {"article": "According to Andrew Lee, co-founder of Medherant, \u201cwe\u2019ve only been in the lab about 12 months, but in the 12 months we\u2019ve essentially assessed about 90 percent of the drugs that are currently available as either creams or patches.\nThe TEPI patch incorporates new adhesive technology developed by global adhesive company Bostik.\nAn ibuprofen patch that delivers the painkiller directly through the skin to the site of pain, at a consistent dose for up to 24 hours, has been developed by UK researchers.\nHe said Medherant\u2019s technology would eliminate most side effects created by oral medication.\nWe\u2019re controlling the dosage and we\u2019re keeping it there for a prolonged period of time.\u201d\n\nThe patches could help treat conditions like chronic back pain, neuralgia and arthritis without the need to take potentially damaging doses of the drug orally.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering here.", "answer": 1}, {"article": "The women who ate more berries also tended to eat healthier overall, consuming more vegetables and fruits than those who didn\u2019t eat as many berries; but when the scientists broke down the women\u2019s diets, they found that the highest consumers of berries even had a lower risk of heart attack compared with women who still ate plenty of fruits and vegetables but fewer berries.\nIt is a powerful message that we can prevent cardiovascular disease by what we eat.\u201d Something worth remembering the next time you\u2019re in the produce aisle.\nWhen we\u2019re making choices in our 20s, we may think that a burger and fries is great, but the message is that there are alternatives that make a difference for the rest of your life.\n\u201cThe take-home lesson is that even if you are eating these early in life, you\u2019re getting benefits that last for life.\nThe researchers focused on blueberries and strawberries because these are the most widely consumed varieties in the U.S.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering.", "answer": 1}, {"article": "\"Many labs are looking at this.\nAug. 3, 2011 -- A new blood test for Alzheimer's disease is 96% accurate at identifying the disease and can perhaps detect it even before symptoms such as memory loss appear, says the test's developer.\nLast month at the Alzheimer's Association International Conference, Australian researchers reported good results for another blood test for Alzheimer's under development.\nHis test is one of numerous such tests under study, says Heather Snyder, PhD, a spokesperson for the Alzheimer's Association, who reviewed the research results.\nNone are highly accurate, and some are costly and not practical to use on a widespread basis, experts say.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\nThe story does not exaggerate the extent or severity of Alzheimer\u2019s Disease. However, it might have been helpful to include some description of the sort of individual who might consider using this sort of test. \n\n\nStories like this need to be clear that since there is no meaningful treatment currently available for Alzheimer\u2019s disease, many individuals may not want to be burdened with the prospect of impending dementia when there is no known way to do anything about it. The story would have been better if rather than focusing on individuals and the fearful prospect of Alzheimer\u2019s, it had given more attention to the most likely near-term use for Alzheimer\u2019s tests: as aids to researchers studying potential treatments in controlled trials.\n", "answer": 1}, {"article": "HPV, a sexually transmitted disease, can be transmitted through vaginal, anal, and oral sex and has been linked to genital warts as well as cervical, vaginal, vulvar, oral, penile, and anal cancers.\n\u201cThe most salient message is that the [Gardasil] vaccine can prevent HPV infection on the external genital region, which means that we can now prevent most cases of genital warts if the boy is vaccinated at a sufficiently early age,\u201d says study researcher Joel Palefsky, MD, a professor of medicine at the University of California, San Francisco.\nThe vaccine is used in girls and boys and young adults ages 9 to 26 for prevention of genital warts caused by HPV types 6 and 11.\nThe vaccine is recommended for optional use in boys and men.\nBoth of these vaccines are recommended to prevent cervical cancers.\n", "question": "Does the story commit disease-mongering?", "explanation": "A thoughtful and careful discussion of the potential risk for genital warts, and the still-uNPRoven connection between the viruses and the development of penile and anal cancers in men. All of this does relate to the number of sexual partners, which the storyr explains.", "answer": 1}, {"article": "Dec. 29, 2009 -- Scientists at the Dana-Farber Cancer Institute say they have developed a compound that may be capable of halting a common type of drug-resistant lung cancer.\nTheir study is published in the Dec. 24/31 issue of the journal Nature.\nThe researchers say their new compound shows how fast lung cancer research and development are moving forward.\nThe researchers say the framework of the new compound is different from that of other cancer drugs and acts against a protein that carries a structural defect, according to a news release.\nThe new compound seems promising in mouse models, the researchers say, adding they hope it proves effective in clinical trials and is better tolerated than drugs now used.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article presents accurate data on lung cancer mortality and NSCLC from\u00a0the American Cancer Society.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070603/11back.htm was not found on this server.", "question": "Does the story commit disease-mongering?", "explanation": "Both spine conditions reported in the news story are real problems for many people. There are no obvious elements of disease-mongering in the story, though its handling of degenerative spondylolisthesis (DS) might lead some readers to conclude that DS is a dire problem requiring surgery, rather than a predicament that might reasonably be treated either surgically or nonsurgically, depending on a patient\u2019s tolerance for risk and preferences. The majority of patients receiving nonsurgical care showed \u201cmoderate\u201d improvement, a fact the news story never mentioned. (See also \u201cEvidence\u201d and \u201cQuantification of benefits\u201d below.) ", "answer": 1}, {"article": "It only finds the damage already done.\nResearchers call it \u201ccompeting mortality.\u201d Finding lung cancer is a hollow victory if patients endure testing and treatment, then die of another illness before the cancer would have killed them.\nIn fact, if screening finds cancer, some seniors won\u2019t withstand the surgery, usually a lobectomy, that may cure it.\nBut it is worth remembering that however effective it is, screening can\u2019t ward off disease.\nThe post-surgical death rate in the national trial was just 1 percent, but that involved major medical centers with specialized radiologists and surgeons \u2014 the ideal setting.\n", "question": "Does the story commit disease-mongering?", "explanation": "In some ways, this story is an example of a way to avoid disease-mongering. Because any Medicare-approved procedure will, by definition, be carried out on elderly individuals, the story\u2019s reflections on \u201ccompeting mortality\u201d\u2014the tendency for older folk to be saddled with multiple chronic diseases\u2014emphasizes the importance of situating lung cancer among the elderly in a larger matrix of health issues. Lung cancer is clearly an important disease, but, as one physician/researcher noted in the story, \u201cIf I find a teensy lung cancer in a 77-year-old with heart disease, I may not have done him any favor.\u201d", "answer": 1}, {"article": "New York Eye and Ear Infirmary of Mount Sinai is ranked No.\n\u201cOur results highlight the need to adopt this practice at acute care hospitals across the nation,\u201d said Dr. Smith.\nThe palliative team was composed of one board certified PC physician, one nurse practitioner, one social worker, a chaplain, and one to two trainees.\nFor more information, visit http://www.mountsinai.org/, or find Mount Sinai on Facebook, Twitter and YouTube.\nThis is the first study to demonstrate that among advanced cancer patients admitted to an inpatient oncology service, standardized use of triggers for palliative care consultation is associated with substantial improvement on multiple quality measures.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in this news release. The severity of terminal cancer could hardly be exaggerated. The release provides useful background on what palliative care is and what it entailed at this hospital.", "answer": 1}, {"article": "But this study doesn't tell us about long-term outcomes or what transpired over a long period of time,\" he said.\nClearly, the earlier a breast cancer is diagnosed, the less treatment that will be required.\n\"There are multiple benefits of mammography in terms of early detection.\nAnd Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society, noted that this was an observational study that only looked at the experience of one institution.\nPort noted that screening guidelines tend to be based on the ability of mammograms to save lives and how often they give a false positive result.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not directly engage in fear-mongering. However, some of the quotes advocating for earlier and more frequent screening play into a scenario that breast cancer is lurking in every woman.\nA discussion of what a woman\u2019s average lifetime risk is would have been helpful.", "answer": 1}, {"article": "\"The work by [first author] Price et al.\nWe should be very careful about claiming the importance of resveratrol for medical purposes.\nBut don't go reaching for that Chianti yet.\n\"This field has been extremely controversial.\n\"A mouse model is not a human being, especially when you are genetically manipulating this animal model, you want to be very careful,\" Marambaud said.\n", "question": "Does the story commit disease-mongering?", "explanation": "Not applicable.\u00a0 Unless we\u2019re talking about aging in mice.", "answer": 2}, {"article": "Our new test is therefore a potential game changer,\" says Professor James Paton, Director of the University of Adelaide's Research Centre for Infectious Diseases.\nThe new blood test has the potential to dramatically improve early detection of the disease, although it will require further testing before it is available for clinicians.\n\"Ovarian cancer is notoriously difficult to detect in its early stages, when there are more options for treatment and survival rates are better.\nResearch on a bacterial toxin first discovered in Adelaide has led to the development a new blood test for the early diagnosis of ovarian cancer - a disease which kills over 1000 Australian women and 150,000 globally each year.\nThe team is currently seeking scientific and commercial partners to further test the technology with larger numbers of patient samples and to adapt it for mass screening.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here. The scope and diagnostic challenges of ovarian cancer are appropriately included.", "answer": 1}, {"article": "Measuring blood levels of the recently discovered hormone irisin may improve diagnosis rates of teenagers with polycystic ovary syndrome, according to research presented today at the 55th Annual European Society for Paediatric Endocrinology Meeting\n\nMeasuring blood levels of the recently discovered hormone irisin may improve diagnosis rates of teenagers with polycystic ovary syndrome, according to research presented today at the 55th Annual European Society for Paediatric Endocrinology Meeting.\nThe cause of PCOS is unknown and there is currently no cure for the condition.\nThe group will next focus on confirming their results and investigate the biological role of irisin in PCOS.\nThe findings may reduce the number of unnecessary treatments prescribed to otherwise healthy girls.\nThe findings suggest that irisin could be a marker for PCOS allowing the condition to be diagnosed more easily.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here. The release says that PCOS \u201cis a common endocrine disorder affecting up to 12% of women\u201d \u2014 and it\u2019s not clear where they got the 12 percent number from. However, that\u2019s not too far off from numbers we\u2019ve seen elsewhere (as high as 10 percent, via NIH), and the language throughout the remainder of the release is responsible.", "answer": 1}, {"article": "Platelet-rich plasma (PRP) is blood that has been spun in a centrifuge to separate the blood cells.\n\u201cPRP is probably the best treatment for chronic refractory lateral epicondylitis if it is used after classical types of treatment like rest, braces, nonsteroidal anti inflammatory drugs, cortisone injections or physiotherapy have all failed,\u201d Thanasas said.\n\u201cThere is now a solution for patients suffering from unrelenting \u2018tennis elbow,\u2019\u201d said Christos Thanasas from Henry Dunant Hospital, Athens, who led the study.\n\u201cWhole blood treatment is a god alternative in remote areas or in health systems that do not support financially the use of PRP,\u201d he told Reuters Health in an email.\nThe findings were published in The American Journal of Sports Medicine.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story nicely avoids disease mongering and, right in the lead, explains that this treatment would work best in patients \u201cwhere other treatment methods have failed\u201d.", "answer": 1}, {"article": "\u201cNow we know that electrical impulses to the olfactory bulb can provide a sense of smell \u2014 and that\u2019s encouraging.\u201d\n\nIn addition to Dr. Holbrook, authors on the International Forum of Allergy & Rhinology study include co-first author Sidharth V. Puram, MD, PhD, of Washington University School of Medicine, Reiner B.\nIn the report, the researchers describe endoscopic procedures to position electrodes in the sinus cavities of five patients with an intact ability to smell.\nThe findings described in the International Forum of Allergy & Rhinology report demonstrate this feasibility.\nReporting online today in International Forum of Allergy & Rhinology, the research team describes their results, which provide a proof of concept for efforts to develop implant technology to return the sense of smell to those who have lost it.\nThere are currently no proven therapies for these cases.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release describes the potential effects of anosmia fairly accurately, consistent with a 2013 study on the consequences of the condition. It also puts the disease in context, describing how many people are estimated to be affected by smell loss.", "answer": 1}, {"article": "In the second study, the researchers found that stool DNA testing had a success rate of 71 percent in detecting serrated colorectal polyps, compared to a 7 percent detection rate with fecal blood tests.\nThe DNA stool test methods were developed at the Mayo Clinic.\n\"The 90 percent detection rate by stool DNA testing is remarkable.\nTUESDAY, May 4, 2010 (HealthDay News) -- Noninvasive stool DNA testing can detect two types of colorectal precancers and could play a larger role in colon cancer prevention, say two new studies.\nSome of the study authors and the Mayo Clinic have a financial interest related to technology used with this research.\n", "question": "Does the story commit disease-mongering?", "explanation": "No overt disease-mongering. ", "answer": 1}, {"article": "\"There's always kind of a 'trend of the week' that you had to go and get tested for and rule out, and at the end of the day you don't feel better,\" she said.\nMaking it worse for many patients, there hasn't been a conclusive test to diagnose what's wrong with them.\nWhile a positive test result is highly suggestive of IBS, only 44 percent of patients with IBS tested positive, meaning that many people who test negative could in fact still have the condition.\nCBS News chief medical correspondent Dr. Jon LaPook, who is also a practicing internist and gastroenterologist, points out that the test is not perfect.\n\"We now have a test to say, you have a disease,\" Pimentel told CBS News.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story says IBS affects 25 million to 45 million people in the U.S. While this may be true, the test we\u2019re talking about isn\u2019t a test for IBS in general \u2014 it\u2019s a test for those with the diarrhea predominant version. It\u2019s not clear how many people this amounts to, but according to this study, less than half of the people with IBS meet the criteria for the diarrhea-predominant version. The story exaggerates the potential impact of the test in a way that promotes a commercial interest, so we\u2019ll flag it for disease mongering.", "answer": 0}, {"article": "Gretchen A. Brenes, Ph.D., of the Wake Forest School of Medicine, Winston-Salem, N.C., and coauthors compared telephone-delivered cognitive behavioral therapy (CBT) with telephone-delivered nondirective supportive therapy (NST) in a randomized clinical trial of 141 adults 60 or older with generalized anxiety disorder.\nThis work was supported by grants from the National Institutes of Health and funding from the Taylor Family Institute for Innovative Psychiatric Research.\nThis work was funded by a grant from the National Institute of Mental Health.\nAt four months\u2019 follow-up there also was greater decline in self-reported GAD symptoms and depressive symptoms among participants in the telephone CBT, according to the results.\nThe clinical trial demonstrated both treatments reduced symptoms of worry, depression and GAD, but telephone CBT was superior to telephone NST and resulted in a greater reduction of symptoms.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release does not demonstrate disease mongering.", "answer": 1}, {"article": "\u201cSome men go to the bathroom several times a night, get right back to sleep and are not bothered,\u201d he said.\nSurprisingly, his case is not unique.\u201d\n\nMany doctors are now urging men to become proactive earlier to prevent chronic problems in the future.\n\u201cThere is a big difference between having the symptoms and being bothered by the symptoms,\u201d said Dr. Kevin T. McVary, professor of urology at the Feinberg School of Medicine at Northwestern University.\nThat is because after age 50 many men face an embarrassing problem called B.P.H., for benign prostatic hyperplasia.\nWatchful waiting, or monitoring symptoms while holding off on medical or surgical treatments, is a reasonable plan for these men, he added.\n", "question": "Does the story commit disease-mongering?", "explanation": "While there was clear that benign prostate hyperplasia was not life threatening and did mention that there is a difference between symptoms and being bothered by symptoms, the story was strongly suggestive that postponing active treatment could have dire consequences without backing this up with information about how commonly serious problems develop.\nAdditionally, the discussion of disrupted sleep was rather specious. Treatments rarely completely eliminate symptoms so the problem of getting back to sleep will still be present.\u00a0 The comment that \"many doctors are now urging men to become proactive\" is difficult to interpret.\u00a0 What data support this statement, how many doctors are there, and who are they?\u00a0 Professional guidelines remain relatively conservative, recognizing that the truly bad outcomes are still relatively uncommon.\u00a0", "answer": 0}, {"article": "SAMe may influence the expression of genes involved in depression or alter the function of different receptors and structures that transport neurotransmitters in the brain.\nDr. Nelson, who was not involved in the Harvard study, said the results need to be replicated in a larger study, and that more information is needed on dosing, side effects and long-term treatment with SAMe, among other things.\n\u201cIt provides clues to new treatments, and it provides clues to understanding what causes depression as well as what goes on biochemically when people get better from depression.\u201d\n\nThe researchers studied the use of SAMe or a placebo in 73 adults with depression who were not responding to prescription antidepressant treatment.\nDr. Papkostas, Dr. Nelson and other researchers involved in the study all disclosed several financial relationships with makers of prescription antidepressants.\nThat\u2019s probably the best hypothesis.\u201d\n\nOther studies have suggested that SAMe can relieve symptoms of depression.\n", "question": "Does the story commit disease-mongering?", "explanation": "We liked how the story restricted the target population to nonresponders. However, we slap its wrist because it said the study was in adults with depression who failed antidepressant treatment. It was actually major depressive disorder and failure of 6 weeks adequately dosed with a specific class of SSRIs. \nFurthermore, it defines \u201cnonresponders\u201d as patients for whom \u201cantidepressants don\u2019t eliminate symptoms.\u201d Eliminate is too strong, and it produces a broader definition of nonresponder than was used in the study. The trial required subjects to have at least a 16 on a particular measurement of depression symptoms, the HAM-D. According to the story, you\u2019d think a nonresponder would be anybody for whom antidepressants didn\u2019t eliminate symptoms (i.e., those with \u201cnormal\u201d HAM-D scores). But that wasn\u2019t the case. Antidepressants may have reduced their symptoms and they could still be nonresponders.\nThe story\u2019s definition of nonresponder is broader than what most clinicians or researchers woul duse; the standard is two or more failed trials. ", "answer": 0}, {"article": "An analysis of 106 randomized trials involving more than 250,000 patients examined the effects of newer angiotensin receptor blockers (ARBs) and older angiotensin-converting enzyme (ACE) inhibitors.\nAccording to the new analysis, published online Jan. 4 in the Mayo Clinic Proceedings, the only difference between the medications is that ARBs are more easily tolerated.\nHowever, when trials were conducted at similar times, one drug was not more effective than the other, the findings showed.\n\"This is the first time that we have a clear and consistent message from the three buckets of trials of ACE inhibitors and ARBs, all of which show that there is no outcome difference between the two agents, except for better tolerability of ARBs,\" Bangalore said.\n\"The results of our analysis are especially important for patients, given that many ARBs are now also generic, which reduces their costs,\" he added.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story does not appear to commit disease-mongering.", "answer": 1}, {"article": "Then, the newly copied viruses break out of the cell, spreading to other cells nearby and repeating the process.\nBoth Japanese and American flu patients were included in the trial.\nRead more at The Wall Street Journal.\nOriginally published on Live Science.\nThe experimental drug worked three times faster than another antiviral drug, Tamiflu, the company told the Journal.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "To place an electronic embedded link to this study in your story: This link will be live at the embargo time: http://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/jamasurg.2016.4219\n\nIn a study published online by JAMA Surgery, Daniel E. Hall, M.D., M.Div., M.H.Sc., of the Veterans Affairs Pittsburgh Healthcare System and University of Pittsburgh, and colleagues examined the effect of a Frailty Screening Initiative (FSI) on death and complications by comparing the surgical outcomes of patients treated before and after implementation of the FSI.\n\u201cThe ultimate cause of the survival benefit is likely multifactorial, including changes in preoperative decision making, intraoperative management, and postoperative rescue,\u201d the authors write.\nEMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, NOVEMBER 30, 2016\n\nAlso available at the For the Media website, the commentary \u201cA Call for Frailty Screening in the Preoperative Setting,\u201d by Anne M. Suskind, M.D., M.S., and Emily Finlayson, M.D., M.S., of the University of California, San Francisco.\n\u201cThis study reveals the feasibility of facility-wide frailty screening in elective surgical populations.\nThe magnitude of improvement among frail patients increased at 180 and 365 days.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No obvious disease mongering in this release.", "answer": 1}, {"article": "Dr. Christopher B. Granger, the study\u2019s lead author and a professor of medicine at Duke University, said, \u201cI think this is a profound trial result that will have a major impact on the practice and management of patients with atrial fibrillation.\nreview later this year.\nThe first new drug, Pradaxa, from the German drug maker Boehringer Ingelheim, was introduced in the United States last fall.\nThe new drugs are not without disadvantages.\nPatents on those drugs expire in the next year, making Eliquis even more important to their businesses.\n", "question": "Does the story commit disease-mongering?", "explanation": "No overt disease mongering.", "answer": 1}, {"article": "Attention, memory, and language improved.\nThe researchers stress that research in this area is important due to the expected extensive population aging over the next 20-30 years.\nMoreover, the benefits to cognition afforded by the MedDiet were not exclusive to older individuals.\n\"The most surprising result was that the positive effects were found in countries around the whole world.\nThe Mediterranean diet can improve your mind, as well your heart, shows a study published in the open-access journal Frontiers in Nutrition.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The issues identified in this study are real ones for all individuals, particularly older ones. This is an important population health problem.", "answer": 1}, {"article": "\"The mounting evidence of caffeine consumption as a potentially protective factor against cognitive impairment is exciting given that caffeine is also an easily modifiable dietary factor with very few contraindications,\" said Ira Driscoll, PhD, the study's lead author and a professor of psychology at the University of Wisconsin-Milwaukee.\nThe paper \"Relationships Between Caffeine Intake and Risk for Probable Dementia or Global Cognitive Impairment: The Women's Health Initiative Memory Study\" is available at: http://biomedgerontology.\nThe findings come from participants in the Women's Health Initiative Memory Study, which is funded by the National Heart, Lung, and Blood Institute.\nIntake was estimated from questions about coffee, tea, and cola beverage intake, including frequency and serving size.\nThis level is equivalent to two to three 8-oz cups of coffee per day, five to six 8-oz cups of black tea, or seven to eight 12-ounce cans of cola.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No mongering here.", "answer": 1}, {"article": "Autistic children are prone to seizures.\nTeresa Badillo was at the meeting.\nLupron therapy grew from the mercury camp.\nThe family put Marco on Lupron about six weeks ago.\n\"The therapy immediately stopped the aggression,\" Badillo said.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering in this story. ", "answer": 1}, {"article": "It\u2019s common for people who suffer from irritable bowel syndrome (IBS) to also struggle with depression.\nMORE: You Asked: Should I Take Probiotics?\nThe probiotics were manufactured and provided by Nestle, which also funded the study.\n(Nestle was not involved in collection, analysis or interpretation of study data.)\nThey were followed for 10 weeks; half took a daily dose of the probiotic , and half took a placebo.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering.", "answer": 1}, {"article": "Why smokers are more susceptible is not known for sure, but some scientists believe it has to do with smoking-caused damage that allows the bacteria to more easily attach to the lungs and windpipe, said Dr. Pekka Nuorti, a medical epidemiologist with the Centers for Disease Control and Prevention.", "question": "Does the story commit disease-mongering?", "explanation": "The story mentions mortality from pneumonia infections in adults over 65 and notes that death from pneumonia is younger people\u2013even smokers\u2013 is relatively rare.\u00a0\n\u00a0", "answer": 1}, {"article": "\"I could ride a bike!\nThe organization creates and shares bionic arm designs for free download at EnablingTheFuture.org that can be assembled for as little as $20 to $50.\nPetresky says they ask every family about the child's favorite color, superhero and interests, so the new limb can \"not just be a piece of plastic ... but be a part of them.\"\nComprehensive statistics aren't available for the number of children with amputations, such as Wyatt.\nFalardeau got in touch with the Orlando students through E-Nable , an online volunteer organization started by Rochester Institute of Technology research scientist Jon Schull to match people who have 3-D printers with children in need of hands and arms.\n", "question": "Does the story commit disease-mongering?", "explanation": "We will give the story a passing mark on this criterion, because it obviously applies only to people who do not have two arms. However, while the story did mention that 3D printers might be able to help provide prosthetic arms to people around the world who do not have access to conventional prosthetic arms, the story would have been better if it provided some explanation of why the patients it profiled would choose a 3D printed arm over any of the other prosthetic arms currently available.", "answer": 1}, {"article": "Plavix is the drug most often used to prevent this complication.\nBut there's a problem with Plavix, and with a newer, stronger drug in the same class called Effient.\nThat's probably why the 6,732 study patients who got Brilinta were 16% less likely to die, or have a heart attack or stroke, than were the 6,676 patients who got Plavix.\nThe new kid on the block is AstraZeneca's ticagrelor, to be named Brilinta if the experimental drug gets FDA approval.\nAnd since the drugs irreversibly bind to blood-clotting platelets, a patient has to stop taking these drugs for five to seven days before the body can make enough new platelets.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0The story indicated that the drug reported on was needed because \u2018blood clots can be a deadly complication of getting a stent\u2019. \u00a0While this is a true statement, it would be more informative to provide some context about how commonly blood clots occur after a person receives a stent. This information would help readers evaluate the importance of a medicine to prevent this from occurring. Nonetheless, we\u2019ll give the story the benefit of the doubt on this. \n", "answer": 1}, {"article": "Statin use may also lead to:\n\u2022 Decreased fibrosis (hardening or scarring of tissue),\n\u2022 Less development of fatty liver,\n\u2022 Slowed or halted spread of hepatitis C virus,\n\u2022 Improvement of portal hypertension (high blood pressure in the liver\u2019s blood vessels),\n\u2022 Destruction of existing liver tumor cells, and\n\u2022 Reduced risk of developing liver cancer.\nNOTE TO JOURNALISTS: To schedule an interview with a member of the research team, please contact the APS Communications Office or 301-634-7209.\nThe article is published ahead of print in the American Journal of Physiology\u2014Gastrointestinal and Liver Physiology.\nFind more research highlights in the APS Press Room.\nThe Society represents more than 10,500 members and publishes 15 peer-reviewed journals with a worldwide readership.\n", "question": "Does the news release commit disease-mongering?", "explanation": "Chronic liver disease is serious and there is no evidence of disease mongering here. Some context about the disease would have been useful for readers.", "answer": 2}, {"article": "When a hookworm crawls into a human, it secretes chemicals that turn off the immune alarm bells and repair the tissue around it.\nThe study is the latest from a surprising field of research into the potentially positive sides of parasites, one of the most maligned groups in the animal kingdom.\nShe wouldn't go so far as to call parasites good.\nIt was important that the participants be adults, because even relatively benign parasites can cause serious problems for children, pregnant women and others.\nAnd because of the risks associated with parasites, going around infecting people isn't a viable treatment option.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article does not engage in disease mongering.", "answer": 1}, {"article": "It also triggers the release of the stress hormone norepinephrine, as well as the mood regulator serotonin.\nThere's more on cancer and hot flashes at the U.S. National Cancer Institute.\nAnd because hormone treatment for breast cancer typically makes the hot flash experience even worse, Razzini added, acupuncture could be a useful tool for helping such patients \"stay on their therapy and improve their quality of life.\"\nDr. Courtney Vito, a breast oncologic surgeon at the City of Hope Comprehensive Cancer Center in Duarte, Calif., was pleased that a serious issue in breast cancer treatment is getting a closer look.\nSo why does acupuncture seem to work?\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here, as hot flashes associated with breast cancer treatments can negatively impact a woman\u2019s quality of life, and treatment decisions.", "answer": 1}, {"article": "For men with advanced prostate cancer, the news for decades has been mostly bleak. Until recently, only two treatments had been shown to prolong survival.\n\nResearchers reported Monday that the drug abiraterone, being developed by Johnson & Johnson, extended survival by an average of 3.9 months among men with cancer that has spread beyond the prostate and for whom other treatments have failed. Among men, prostate cancer is the second-leading cancer killer, behind only lung cancer.", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\n \nThe story points out that the drug has been tested only in patients with advanced disease who have tried other treatments. However, the story expands the definition of who stands to benefit by raising hopes that future studies will show effectiveness in patients with less advanced disease, even though such trials have yet to begin. Furthermore, extending these new treatments to earlier-stage disease is  problematic given the known risks for already overtreating many of these  patients.  The final quote that sequentially using the various new  medications could further extend life is troubling because there is no  evidence for this strategy\u2013which could also be very expensive. That quote could have been challenged. \n The statement that prostate cancer is second only to lung cancer as a killer of men creates a troubling comparison that obscures that fact that while most lung cancer patients die of their disease within a couple of years of diagnosis, most men diagnosed with prostate cancer ultimately die of something else after many years of life.", "answer": 0}, {"article": "\u201cTaking care of your vision is important in order to maintain good cognitive function,\u201d she said in a telephone interview.\nPoor eyesight and weakening mental function are common in older people and related to one another, but the question of whether vision influences cognition, or vice versa, has not been clear, the study team writes in JAMA Ophthalmology.\nThe good news, Whitson added, is that poor vision is one of the few risk factors for cognitive decline that is potentially modifiable.\nThe results suggest that vision fixes, like a new eyeglass prescription or surgery to remove cataracts, can go a long way toward helping older people stay mentally sharp, said lead author D. Diane Zheng of the University of Miami Miller School of Medicine.\n\u201cThis study provides additional evidence that would suggest that people who can keep their vision healthy as they age might also be protecting their cognitive health,\u201d said Dr. Heather E. Whitson of Duke University School of Medicine and Durham VA Medical Center, who wasn\u2019t involved in the research.\n", "question": "Does the story commit disease-mongering?", "explanation": "Both cognitive decline and vision loss accompany aging.\u00a0 Neither is necessarily lethal, but seeking to learn if they are related would be beneficial.\u00a0 An invited commentary that accompanied the report of this research in the Journal of the American Medical Association Ophthalmology describes a number of studies exploring this relationship in recent years,", "answer": 1}, {"article": "The study, conducted in conjunction with the University of Washington, involved 56 men who were assigned to receive one of three types of gels: one gel containing both testosterone plus a gel containing one of two doses of the synthetic progestin; or a gel containing testosterone on its own plus a \"placebo\" gel with no progestin.\nOne important and unanswered question is what the long-term side effects of this regimen might be.\nThere's more on contraception at the American College of Obstetricians and Gynecologists.\nAnother question is how reversible this would be in terms of restoring sperm counts, Alukal said.\nAlthough men have sometimes received a bad rap for not being willing to assume responsibility for birth control, Dr. Joseph Alukal, an assistant professor of urology at NYU Langone Medical Center, in New York City, thinks this reputation may be somewhat undeserved.\n", "question": "Does the story commit disease-mongering?", "explanation": "Providing alternative contraception options for men is an important issue, as the story suggests.", "answer": 1}, {"article": "First week control data were collected for 7 successive days.\nLuckily, as we show in our research, melatonin helps to ameliorate both trends.\nIn conclusion, melatonin can be of great value for aged people suffering from hypertension as an adjuvant substance complementing basic medication as it is able to stabilize circadian BP, heart rate profiles and their phase relationships.\nMoreover, the higher the mean systolic BP was during the first week, the more it dropped on the second week of melatonin administration.\nNone of these effects was found in 34 placebo treated seniors, thus ruling out the possibility that rhythms could be improved just because of regular schedule and presence of medical personal who took measurements.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release is correct to note that circadian rhythms in the elderly get disrupted and can make getting a good night\u2019s sleep more challenging. But should we regard this process as an illness requiring treatment? Those with hypertension should certainly care, but it is not clear that waking up more often during a night qualifies as a medical problem for many older individuals.\nWe found this quote a bit troubling: \u201cThe older we get, the more likely our circadian rhythms are disrupted. For example, blood pressure (BP), not only tends to increase but as well become more irregular. Luckily, as we show in our research, melatonin helps to ameliorate both trends.\u201d\u00a0\u00a0This \u2018process\u2019 of blood pressure variability may in fact be normal physiology and is not necessarily the culprit for poor sleep.", "answer": 0}, {"article": "However, common side effects included headache, dizziness and nausea.\n\"If weight-loss drugs are tailor-made to hit only the right receptor, based on physiological knowledge, it seems to be possible to develop weight-loss medications that do not possess any serious adverse effects,\" Astrup added.\n\"Among those who remained, lorcaserin produced relatively modest weight loss when combined with diet and exercise counseling, and that weight loss was maintained in over half of the participants only so long as they kept taking the drug.\nWEDNESDAY, July 14, 2010 (HealthDay News) -- A weight-loss pill called lorcaserin not only helps people drop pounds but does so with few side effects, new industry-funded research reports.\n\"This close look at lorcaserin reaffirms that better daily use of feet and forks holds far greater promise for meaningful, sustainable and affordable weight control than pharmacotherapy,\" Katz said.\n", "question": "Does the story commit disease-mongering?", "explanation": "The second sentence begins, \"A potential player in fighting the obesity epidemic.\" That is the sole reference to the problem of obesity, and, although it contributes to the framing of\u00a0obesity as a disease that needs medication versus a risk factor for disease that can be altered with lifestyle changes, it doesn\u2019t quite register as disease mongering. So we judge this\u00a0 to be satisfactory. ", "answer": 1}, {"article": "Asthma patients suffer fewer attacks and need fewer hospital visits.\n\u201cIt\u2019s not going to get rid of asthma, but it is going to reduce symptoms and hospitalizations and make patients more functional in their daily life.\u201d For now, the procedure is only for severe asthmatics, who \u2014 unlike a vast majority of asthma patients \u2014 cannot keep flare-ups at bay with standard medications, said Dr. Kyle Hogarth, an assistant professor of medicine at the University of Chicago who was involved in clinical studies of the treatment.\nSince then, about 650 patients across the country have had the procedure.\n\u201cThere will not be millions of thermoplasty patients.\u201d\n\nStill, even patients with severe asthma often are denied insurance coverage for the procedure.\nThe one-time cost of $20,000, they say, is dwarfed by the tens of thousands of dollars in hospital bills and medication costs that a severe asthmatic can easily accumulate in a single year.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story notes that the procedure\u00a0\u201cis only for severe asthmatics, who \u2014 unlike a vast majority of asthma patients \u2014 cannot keep flare-ups at bay with standard medications.\u201d", "answer": 1}, {"article": "He explained: \"When teixobactin was discovered it was ground breaking in itself as a new antibiotic which kills bacteria without detectable resistance including superbugs such as MRSA.\nWe have been investigating a way to simplify the design while retaining the high potency against resistant bacteria such as MRSA.\nThe breakthrough by researchers at the University of Lincoln, UK, marks another important step to realising the potential of teixobactin in aiding the global fight against antibiotic-resistant pathogens.\nIt has been predicted that by 2050 an additional 10 million people will succumb to drug resistant infections each year.\nTeixobactin is a recently discovered natural antibiotic which many in the international scientific community believe could lead to creation of the first commercially viable new antibiotic drug in 30 years.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t disease monger. There is no doubt that antibiotic resistant infections are a widespread and growing threat.", "answer": 1}, {"article": "WASHINGTON -- The Food and Drug Administration on Wednesday approved ImClone Systems Inc. and Bristol-Myers Squibb Co.'s Erbitux as a treatment for head and neck cancer, the agency said Wednesday.\n\nThe drug, which is designed to block proteins involved with cancer growth, was first approved in 2004 as a colon cancer treatment.", "question": "Does the story commit disease-mongering?", "explanation": "There is no obvious disease-mongering. The story accurate represents the prevalence and seriousness of head and neck cancer.", "answer": 1}, {"article": "An inexpensive drug therapy far surpassed a conventional laser procedure in fixing a leading cause of blindness in babies born prematurely, according to a new study.\n\nThe results of the study, to be published this week in the New England Journal of Medicine, were so significant that the 15 hospitals participating in the research have stopped using lasers in favor of the drug, Avastin, which is injected into the eyes of the affected newborns. Avastin, made by Roche Holding AG's Genentech unit, is designed to be used for treating...", "question": "Does the story commit disease-mongering?", "explanation": "There\u2019s no real mongering here.\nAs a side note, the article cites statistics regarding the disease in general. Since the study only enrolled a subset of babies with this disease, it would be interesting to know how representative its sample was.", "answer": 1}, {"article": "Watch Sanjay Gupta MD Saturday at 4:30pm and Sunday at 7:30am ET.\nA calcium score would answer that question, she says.\n(Agatston does not make any money from the coronary calcium scan.)\nThere's a third test Agatston likes: a $65 blood test that looks at a patient's LDL, or bad cholesterol.\nAgatston says relatively new imaging tests give real-time pictures showing whether plaque is building up in key blood vessels, alerting doctor and patient to an increased risk of a potentially deadly heart attack.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story exemplifies disease-mongering by highlighting threats of terrible consequences and wildly exaggerating the number of people likely to benefit from these scans. With statements like, \u201cunless you do imaging, you are really playing Russian roulette with your life\u201d and \u201cAgatson thinks that the coronary artery calcium scan should be routinely scheduled at age 50\u2026\u201d provide the uninitiated reader with the impression that everyone needs one of these tests.\u00a0 While the comments of Dr. Michos modify the unabashed enthusiasm, the overall tenor is over the edge.", "answer": 0}, {"article": "In the September issue of Cancer Prevention Research, researchers report that metformin was associated with a substantial reduction (up to 73 percent) in the number of tumors mice developed when they were given a common carcinogen found in tobacco.\nAnd when the drug was administered by injection, the improvement seen was 73 percent.\nThe reduction is real and ranges from 30 to 70 percent.\"\nAnderson Cancer Center in Houston, at a Wednesday news conference.\nThe drug was approved by the FDA in the mid-1990s.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering in this story. ", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070513/21sunscreen.htm was not found on this server.", "question": "Does the story commit disease-mongering?", "explanation": "There is persuasive evidence linking exposure to the sun\u2019s ultraviolet rays to melanoma, a formidable and sometimes fatal skin cancer, as well as to skin wrinkling and age spots, in certain individuals. The article mentions this link once, but does not dwell on it.", "answer": 1}, {"article": "Lauren Dunn is a medical producer for NBC News; Linda Carroll is a contributor for NBCNews.com\nAlso, Hamilton notes, the implants aren\u2019t a \u201cbe all end all.\nIt\u2019s functioning in your day-to-day life.\u201d\n\nEkstadt has the privilege of being the first person in the nation to get the Raindrop outside of a clinical trial.\nBut that may be changing.\nAnd now she\u2019s able to read without the aid of glasses.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering, though including everyone older than\u00a035 years old in the \u201caging\u201d category may have been overkill.", "answer": 1}, {"article": "That\u2019s likely because experts believe that as Alzheimer\u2019s progresses, more of the protein plaques form in the brain, and less of the protein is released to the rest of the body.\nThe study included men and women.\n\u201cBut that did not happen.\nPlus, he says, resveratrol supplements currently available over the counter are \u201cunregulated and we don\u2019t know how much is in it.\nEven more encouraging, the people who were treated showed slight improvements in their ability to maintain certain daily activities on their own, such dressing and bathing themselves.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "You've probably heard about it \u2014 maybe you even remember seeing it once \u2014 but you're not really sure what it is or even where to find it.\n\nThe female condom (FC2), or internal condom, is a non-hormonal barrier method of birth control. But instead of going on a penis, it goes in a vagina, which is why it's also sometimes referred to as an internal condom. For more information, BuzzFeed Health spoke with two experts who could demystify this lesser-known contraceptive:\n\n* Dr. Harry Fisch, clinical professor of urology and reproductive medicine at Weill Cornell Medical College, and chief corporate officer of Veru Healthcare, which distributes FC2\n\n* Dr. Lauren Streicher, associate clinical professor of obstetrics and gynecology at Northwestern University\u2019s Feinberg School of Medicine", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering. We also applaud the context in behavioral and financial realities that is part of the story.", "answer": 1}, {"article": "In the study of 35,016 older women with no history of breast cancer, those who reported currently taking fish oil supplements on a regular basis had a 32% reduced risk for developing invasive ductal breast cancer, compared with women who did not take fish oil supplements.\nThe use of fish oil was linked to lower risk of invasive ductal breast cancer.\nThe new research is part of the Vitamins and Lifestyle (VITAL) study, which included data from women 50 to 76 years old from Washington state.\nOther supplements were not linked to breast cancer risk in the new study, including black cohosh, dong quai, soy, and St. John's wort, which are often taken to relieve some of the symptoms of menopause.\nExactly how fish oil may affect breast cancer risk is not fully understood, but it may be related to its strong anti-inflammatory properties.\n", "question": "Does the story commit disease-mongering?", "explanation": "No overt disease mongering. ", "answer": 1}, {"article": "The drug is approved by the FDA only for traveler's diarrhea and hepatic encephalopathy, a brain disorder caused by chronic liver failure.\nWith the drug treatment, Pimentel says, those with the IBS ''can enjoy social outings without the worry of having to run to the bathroom and having diarrhea.\"\nThe study looked only at those IBS patients with the non-constipation form, he tells WebMD.\nThat can translate to big changes in the lives of those with IBS, estimated to affect about 15% of adult Americans.\n''The major finding was that all IBS symptoms improved,\" says Mark Pimentel, MD, director of the GI Motility Program at Cedars-Sinai Medical Center, Los Angeles, who led the clinical trial of the drug at Cedars.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in disease-mongering and presented the information about the disease in a straightforward way. \u201cThe study looked only at those IBS patients with the non-constipation form, he tells WebMD. For those with this type of IBS, symptoms can include abdominal pain, bloating, and changes in bowel function such as diarrhea.\u00a0IBS is considered a functional gastrointestinal disorder without a known physiologic cause, with the symptoms recurring and often worsened by stress. Existing treatment options \u2014 diet and lifestyle modification, psychological therapy, and other drugs \u2014 do not help all people with the condition.\u201d", "answer": 1}, {"article": "But in some people HPV leads to genital warts and cancers \u2013 notably, cervical cancer.\nKissing is not known to deliver this STD.\nThe researchers did not observe any side effects.\nGiven those drawbacks, it\u2019s not appropriate to draw too many conclusions from this study, says Dr. Diane Harper, a prominent HPV researcher at the University of Missouri \u2013 Kansas City\u2019s School of Medicine.\nThe vaccine consists of three injections in the arm over three months, Kim said.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not appear to commit disease mongering.", "answer": 1}, {"article": "\"Normally when you make drugs, it's hard to say 'attack only that protein.'\nBut the work that nabbed the prize was done in worms -- a far cry from humans.\nThere's more on RNA interference at the Howard Hughes Medical Institute.\nAnd there were other challenges, not the least of which was how to get the siRNAs into the appropriate cell and then make sure they did what they were supposed to do.\nThe experiment proceeded just as planned, as biopsies later showed.\n", "question": "Does the story commit disease-mongering?", "explanation": "Not applicable because no diseases were discussed in any detail. ", "answer": 2}, {"article": ".\nThe study demonstrates that patients with GTPS can get similar results from dry needling as from a steroid injection.\nThe study is titled \"Dry Needling Versus Cortisone Injection in the Treatment of Greater Trochanteric Pain Syndrome: A Noninferiority Randomized Clinical Trial.\"\nHowever, \"this study suggests dry needling as an effective alternative to cortisone injection.\"\nThe results showed that cortisone injection did not provide better outcomes than dry needling for either pain or function in patients with GTPS.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease mongering. Hip dysfunction is very common, and the news release doesn\u2019t appear to overstate that. It says GTPS \u201cis estimated to affect 10% to 25% of the general population. This kind of hip pain has been reported to be more common in women and in patients with coexisting low back pain, osteoarthritis, Iliotibial band tenderness, and obesity.\u201d", "answer": 1}, {"article": "MILAN, ITALY, Sept. 12, 2017 - An antibody treatment reduces the rate of flare-ups by nearly 20 percent in patients with a subgroup of treatment-resistant chronic obstructive pulmonary disease (COPD), according to the results of two large international trials presented today at the European Respiratory Society International Congress in Milan, Italy, and simultaneously published in the New England Journal of Medicine.\nThe METREO results narrowly missed statistical significance.\n\"We hoped to be able to offer them an option.\"\nThe 300-milligram dose did not provide an advantage over the lower dose.\nThe first trial, termed METREX, was conducted at 117 sites in 15 countries from 2014 to 2017.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "Participants in the active arm of the study received 248 milligrams of elemental magnesium per day over six weeks, while those in the control arm received no treatment.\n\"The results are very encouraging, given the great need for additional treatment options for depression, and our finding that magnesium supplementation provides a safe, fast and inexpensive approach to controlling depressive symptoms.\"\nNew clinical research published today in PLoS One shows that over-the-counter magnesium appears safe and effective to treat mild to moderate depression.\nDepression presents an enormous disease burden, with a reported 350 million people worldwide suffering from the disease, but traditional SSRI treatments carry a burden of their own - in dollars and side effects.\nTarleton and colleagues say the next step is to see if their promising results can be replicated in a larger, more diverse population.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease-mongering here. The news release called depression an \u201cenormous disease burden.\u201d This is true\u2014depression is a huge problem that affects millions of people. The World Health Organization says more than 300 million people worldwide suffer from depression.", "answer": 1}, {"article": "Parkinson's disease is a neurological disorder that can cause tremors, stiffness, slowness of movement, trouble balancing, problems walking and difficulty coordinating movement.\nMeanwhile, doctors are not always correct, Wright said.\nAn accurate blood test, then, would be good news in these situations.\nThough other symptoms will show up eventually and help in diagnosing the patient, in the meantime, the patient will be receiving the wrong medicines.\nStill, Wright is hopeful and believes a biomarker test for Parkinson's \"will be down the line.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not disease monger, and it did a nice job describing how common these atypical diseases are, compared to Parkinson\u2019s disease.", "answer": 1}, {"article": "Brain scans and spinal taps are helpful but they're not certain.\nToday only an autopsy can establish for sure that a patient had Alzheimer's.\nThere is still plenty of lab work to be done, more rigorous research before it's proven a simple blood test can diagnose Alzheimer's, but those working on the test are hopeful it can be approved for use by 2009, adds Blackstone.\nAccording to a paper published in the online edition of the British journal Nature Medicine, preliminary studies by a team of scientists led by a Stanford neurology professor show the test is yielding promising results in predicting which patients with mild memory loss are at high risk of developing Alzheimer's disease.\nCurrently, an early Alzheimer's diagnosis requires complex brain scans.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate the problem and prevalence of Alzheimer\u2019s disease.\u00a0 However, by repeating the mantra that an early diagnosis by a blood test is a good thing, one is led to believe that there is an intervention that may be widely applicable. (It states: \"For millions who worry their forgetfulness could be the first sign of something worse, a blood test could, in the future, provide answers.\")\u00a0 In this sense, there is disease mongering by implying many could benefit from this test when the notion of benefit is speculative at best.", "answer": 0}, {"article": "(Reuters Health) - Exposing sleeping people to a series of short flashing lights at night might help them adjust more quickly to time zone changes, according to a new U.S. study.\n\u201cJet lag itself is really a nuisance syndrome as it is self-resolving,\u201d said senior author Jamie Zeitzer, assistant professor of psychiatry and behavioral sciences at the Stanford University School of Medicine in California.\nAs for frequent flyers trying this themselves, it is \u201cfar too early \u2013 neither the methodology is available outside research, nor any guidance about safety, nor tests of simulated jet lag in an appropriate \u2018realistic\u2019 protocol,\u201d Wirz-Justice told Reuters Health by email.\n\u201cHowever, the treatments that are developed for jet lag can be used for less prevalent, though far more significant societal problems including delayed sleep in teens (in whom we have an ongoing clinical trial using the flash technique) and shift workers who try to flip between a night time schedule for work and a day time schedule for leisure,\u201d he told Reuters Health by email.\nIn experiments, the technique \u2013 which is based on the way non-visual parts of the brain respond to light \u2013 was much more effective than sustained bright light similar to that from devices sometimes used to combat sleep disorders or seasonal depression.\n", "question": "Does the story commit disease-mongering?", "explanation": "The report included this helpful phrase to indicate that this isn\u2019t a \u2018real\u2019 disease: \u201c\u2019Jet lag itself is really a nuisance syndrome as it is self-resolving,\u2019 said senior author Jamie Zeitzer, assistant professor of psychiatry and behavioral sciences at the Stanford University School of Medicine in California.\u201d", "answer": 1}, {"article": "PAE reduced the symptoms of frequency and urgency of urination without causing side effects like incontinence, sexual dysfunction, retrograde ejaculation (ejaculation into the bladder), or bleeding.\nThe study was presented at the Society of Interventional Radiology annual meeting in Chicago.\n\u201cThere are a lot of questions.\n\u201cIt was my inspiration -- uterine fibroids.\nDespite the promising results of this small trial, experts said it was far too early to recommend PAE to patients.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story provided the reader with the fact that benign hyperplasia affects 19 million American men without any additional context about the men affected. \u00a0It would have been useful, for example to explain that this was a chronic condition that becomes more common as men age; some men find their symptoms severe enough to seek treatment; others are less bothered by the condition. BPH is not likely to cause serious complications. There are men who choose to watch and wait, and who bypass treatment entirely. You\u2019d never get that notion from this story.", "answer": 0}, {"article": "Sorry. The page you requested is not available", "question": "Does the story commit disease-mongering?", "explanation": "The article does nothing to exaggerate the severity or consequences of MS.", "answer": 1}, {"article": "After first taking in \u201craw data\u201d of an image through the eye, different sets of neurons in the brain process it as separate features like edges and colors.\nHowever, other studies with no commercial links obtained similar results, and several scientists I spoke to, including those without ties to GlassesOff, thought the science behind the app was credible.\nScientists don\u2019t know exactly how perceptual learning relieves presbyopia, but they have some clues based on how our brain processes visual information.\nIt should be acknowledged that some researchers involved in many of these studies have financial ties to GlassesOff.\nVarious smartphone apps say they offer this kind of vision-improving training; I used one called GlassesOff, the only one I found that was backed by scientific studies.\n", "question": "Does the story commit disease-mongering?", "explanation": "Comments about bifocal-wearing contributing to accidents are arguably on the line of disease mongering. In the linked study cited to support this point, there was no statistically significant difference in falls between groups that had bifocals or who wore single lens glasses. But, we\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "When treating a patient suffering from depression, Brent Forester considers which anti-depressant to prescribe\u2014ideally, one that will ease psychic pain without side effects.\n\nIt can be a tough call.", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here; moderate to severe depression is a real and prevalent disorder and danger. We also thought it was wise how the story included a patient narrative with unclear results\u2013she\u2019s feeling better, but not 100%. That is a very powerful way to explain that this new tool isn\u2019t a silver bullet.", "answer": 1}, {"article": "To make sure it works, though, the Centers for Disease Control and Prevention says doctors need to do a number of things:\n\u2022 Prescribe Truvada only for men at high risk of getting infected \u2013 that is, only for men who have sex with men, those who have multiple sex partners, and those who live in areas where there's a lot of HIV circulating.\nThat doesn't tell the whole story.\nThat touched off a lot of celebrating.\nSome insurers might pay, but some might balk.\nThe study makes that last point very clear.\n", "question": "Does the story commit disease-mongering?", "explanation": "NO disease-mongering here.", "answer": 1}, {"article": "DALLAS - April 18, 2016 - A five-year study shows that Stereotactic Body Radiation Therapy (SBRT) to treat prostate cancer offers a higher cure rate than more traditional approaches, according to researchers at UT Southwestern Medical Center Harold C. Simmons Comprehensive Cancer Center.\n\"The current form of radiation is 44 treatments given over nine weeks.\nThe faculty of almost 2,800 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments.\n\"SBRT is both more convenient and has increased potency.\"\n\"I live 45 minutes away from UT Southwestern.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering.", "answer": 1}, {"article": "A little bit of current may calm the tremors of Parkinson\ufffds disease, ease depression and epilepsy, and awaken those with terrible injuries.\nA glimpse of Mom must first register on your occipital lobes as a pattern of light and shadow.\nIt's harder than you think to say hello to your mother--at least in terms of the work your brain has to do.\nFrom there it is relayed to your memory center, where it is identified by comparison with every other face you've ever seen.\nThe fact that recognizing and acknowledging a familiar person is such...\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in overt disease mongering.", "answer": 1}, {"article": "In a study published in the journal Aging, Bredesen and colleagues showed how 10 patients who were experiencing age-related memory decline showed brain scan improvements after following an approach called metabolic enhancement for neurodegeneration (MEND), a 36-point individualized regimen of diet, exercise, brain stimulation, sleep improvements, medication and vitamins and other specific protocols for five to 24 months.\nBut even if MEND is effective, the program is complex and difficult to follow.\nA cure for Alzheimer's disease (AD), a condition marked by progressive, debilitating cognitive decline that affects more than 5.4 million Americans, is the holy grail in disease research.\nOne expert, Dr. Dale Bredesen, a professor at the Buck Institute for Research on Aging and a professor at the Easton Laboratories for Neurodegenerative Disease Research at UCLA, thinks he might have found a way to reverse memory loss, a hallmark of the disease.\nGalvin agrees that more research is necessary before any conclusive results can be reported.\n", "question": "Does the story commit disease-mongering?", "explanation": "There\u2019s no exaggeration of the seriousness of Alzheimer\u2019s. However, the story should have been more careful in its wording. Calling a cure for Alzheimer\u2019s \u201cthe holy grail in disease research\u201d isn\u2019t accurate. There are plenty of horrible illnesses for which cures are being actively sought.", "answer": 1}, {"article": "A new study finds that supplementing the Mediterranean diet with more olive oil or more nuts helps diminish age-related decline in cognitive function. Photo: Getty Images\n\nThe Mediterranean diet, supplemented with a handful of nuts or a few tablespoons of olive oil a day, can counteract the effects of aging on the brain\u2019s ability to function, a new clinical study suggests.\n\nThe study, published online Monday in JAMA Internal Medicine, was unusual in that it employed rigorous scientific practices to test the effect of the diet on health. Most previous evidence showing benefits from the Mediterranean diet was gathered through observational studies, a less conclusive research technique.", "question": "Does the story commit disease-mongering?", "explanation": "The story does not overplay the import or incidence or cognitive decline.", "answer": 1}, {"article": "It\u2019s actually a double breakthrough,\u201d said Professor Graham.\nThis will enable doctors to identify those women who are at greatest risk of having a baby with a birth defect, and ensure they are getting sufficient vitamin B3.\n\u201cJust like we now use folate to prevent spina bifida, Professor Dunwoodie\u2019s research suggests that it is probably best for women to start taking vitamin B3 very early on, even before they become pregnant.\nThis breakthrough, led by Professor Sally Dunwoodie from the Victor Chang Institute, has identified a cause of recurrent miscarriages as well as heart, spinal, kidney and cleft palate problems in newborn babies.\nThis discovery is akin to the revolutionary breakthrough made last century that confirmed folic acid supplementation can prevent spina bifida and other neural tube defects in babies.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering. The study rightly points out that miscarriages and birth defects affect millions of families worldwide.\u00a0", "answer": 1}, {"article": "Washington University School of Medicine's 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children's hospitals.\nNo patient died during the trial.\nSo our goal is to make warfarin safer.\nThe adverse events were bleeding, formation of blood clots in the veins and warfarin overdoses.\n\"Although genetic testing is more expensive than clinical dosing, the cost is falling,\" he said.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No mongering here.", "answer": 1}, {"article": "In one study, researchers found that people who have long telomeres, the small strips of DNA that cover the ends of chromosomes, have a 30 percent increased risk of developing colon cancer.\n\"Hopefully, this is a good start for a more reliable test.\"\n\"These findings are interesting,\" he said.\n\"They will be more interesting if we ever get this kind of data in a screening population.\"\nCologuard is not yet available for sale.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "\"There's no magic in a liter-and-a-half,\" he said.\nDr. Susan Bleasdale, medical director of infection control at the University of Illinois at Chicago, said the study \"may be a game changer\" for antibiotic \"stewardship\" programs aimed at reducing inappropriate antibiotic use.\nWhether the advice would benefit women with normal urine output, however, is unclear, Wessells noted.\nYoung women plagued by UTIs who drank an additional 6 cups of water each day were nearly half -- 48 percent -- as likely as a control group to have another infection, the study showed.\nShe cited a 2010 review estimating that 11 million to 12 million women a year will suffer from a UTI, accounting for 1.6 billion antibiotic prescriptions a year.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not disease-monger and it discussed the prevalence of UTIs and why they affect women more often. However, we think it could have dialed back some of the predictions that this could lead to the end of antibiotic use for UTIs.", "answer": 1}, {"article": "Some 68% of the country is either overweight or obese, but there\u2019s not much clinical evidence on the best way to lose weight, outside of research on bariatric surgery. (True, \u201cEat less and exercise more\u201d is great advice if you can manage to follow it, but public-health authorities have repeated that line until they\u2019re blue in the face and as a population we\u2019ve only gotten fatter.)\n\nResearch presented over the weekend at the annual meeting of the Obesity Society and published online in the Journal of the American Medical Association suggests a few specific strategies that may help \u2026", "question": "Does the story commit disease-mongering?", "explanation": "The story repeats the commonly cited CDC statistics on people who are obese and overweight. It does not engage in disease-mongering.", "answer": 1}, {"article": "Other scientists and companies have long sought ways to measure risk from multiple, additive gene effects \u2014 the \"poly\" in polygenic \u2014 and Myriad Genetics has begun selling a type of polygenic test for breast cancer risk.\nAn unhealthy lifestyle could overwhelm the protection of good genes.\nIt doesn't require the most sophisticated type of genetic testing.\nEach variation alone would have only a tiny effect on health.\nBut specialists in heart disease and genetics who weren't involved with the research called the new findings exciting because of their scope.\n", "question": "Does the story commit disease-mongering?", "explanation": "No apparent disease mongering here.", "answer": 1}, {"article": "In the case of microablative fractional CO2 laser surgery, a series of microscopic laser beams using fractionated energy penetrate the skin to remove old and damaged skin cells, intended to rebuild the vaginal pathway.\n\"This study adds to the literature on vaginal laser therapy for GSM.\n\"Until more data are available, all treatment options, including lubricants, vaginal moisturizers, and FDA-approved vaginal and systemic hormone therapies, should be discussed with women who suffer from GSM to determine the best treatment option for them.\"\nFor more information about menopause and healthy aging, visit http://www.\nHowever, more robust randomized, sham-controlled data are needed, with larger numbers of women, to evaluate long-term safety, benefits, and risks,\" says Dr. JoAnn Pinkerton, NAMS executive director.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release tells us that \u201cpainful sex, dryness, itching/burning, urinary frequency, and incontinence\u201d are symptoms and signs associated with menopause. We\u2019re also told that \u201ccollectively\u201d these represent genitourinary syndrome of menopause (GSM) which the gynecologic literature\u00a0variably describes as either a \u201ccondition\u201d or a \u201cconstellation of symptoms\u201d associated with low estrogen levels in women. (See this helpful essay from Harvard Women\u2019s Health Watch.)\nSome readers might be left wondering: \u201cSo is GSM a disease? Do I need to have all the symptoms to qualify? Aren\u2019t many of these symptoms part of \u2018normal\u2019 menopause? Or, is having such symptoms abnormal and should therefore be treated?\u201d\nWe wish the news release had made it clear that these symptoms can represent normal aspects of aging that many women choose to manage with non-pharmacologic and non-surgical approaches.\nWe\u2019ll give this the benefit of the doubt and rate this satisfactory since it\u2019s debatable whether or not this news release disease mongers.", "answer": 1}, {"article": "Something similar is likely happening, he added, with electroconvulsive therapy (ECT), or what is sometimes referred to as \u201celectroshock treatment.\u201d Sixty to 70 percent of depressed people who undergo ECT, in which electrodes placed on the front of the brain induce a convulsion while the patient is anesthetized, will recover.\n\u201cI\u2019m optimistic that it\u2019s pointing us in a path of understanding how to interact with the brain in a non-invasive way to get people well.\u201d\nHow long the treatment should last is not yet clear.\nIn a second phase of the study, all patients were given the real TMS treatment.\n\u201cIt looks as if from this trial you at least need to try three weeks and maybe even six weeks before you would give up.\u201d\n\nPatients who got better were prescribed venlafaxine - marketed as Effexor \u2014 and a small dose of lithium, noted George, a combination that\u2019s been shown to help people stay well after their depression has remitted.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story doesn\u2019t resort to disease-mongering.", "answer": 1}, {"article": "Prostate cancer becomes more common as men age \u2014 autopsies of elderly men find that most had prostate cancer, whether they knew it or not.\nBut some said that if the test leads to more screening, it is not necessarily a good thing.\nIt was released online on Wednesday, a journal spokeswoman said, because \u201cit is a very active area of research with a lot of competition.\u201d\n\nResearchers long knew that the disease often runs in families.\nStill, he said the new test could help patients if it was used with caution.\n\u201cWe are just feeding off of this cancer phobia.\u201d\n\nWhat is needed, and what the new test does not provide, is a way to decide which cancers are dangerous and which are not, Dr. Isaacs said.\n", "question": "Does the story commit disease-mongering?", "explanation": "A couple of the quotes border on disease-mongering when discussing the prospect of earlier prostate cancer screening \u2013 even in men in their 30s.. However, the story attempted to provide some context with expert comment questioning the wisdom in this approach.", "answer": 1}, {"article": "One of the most frustrating aspects of brain injuries is that they can be difficult to diagnose; emergency rooms can sometimes miss subtle symptoms, leading to improper treatment and potentially catastrophic consequences. Now, researchers are close to identifying so-called biomarkers that may soon make it possible to pinpoint brain injuries with a simple blood test.\n\nPresence of these biomarkers\u2014proteins produced by an injured brain\u2014could end up determining the future treatment of the estimated 1.4 million athletes, car-crash...", "question": "Does the story commit disease-mongering?", "explanation": "We think this article does engage in disease-mongering. The statistical sidebar cites some grim outcomes of head trauma. These numbers cloud the point of the story, which is about undiagnosed or slow-to-diagnose cases. How many of the\u00a03 million people who need long-term care\u00a0and\u00a0the 52,000 who died had\u00a0undiagnosed\u00a0severe brain injuries? How many died on contact?\u00a0How often\u00a0does the current diagnostic approach fail?\u00a0In other words,\u00a0who exactly might this new technique benefit?\u00a0While perhaps no one knows those answers, we think the overly general sidebar inflates the expectations balloon too much.\nAnother point that was easy to miss: the tests in humans measured UHC-L1 in spinal fluid. That requires a spinal tap. While it\u2019s something one might consider in the first scenario, it\u2019s unlikely to be practical for the second. One would expect that the test characteristics of a CSF level are different from a blood level.\u00a0", "answer": 0}, {"article": "The risk of having a baby with Down\u2019s \u2014 which occurs when a child has three copies of chromosome 21 instead of the normal two \u2014 increases sharply as women get older.\nThe risk for a 40-year-old mother is 16 times that for one who is 25.\nPatsalis\u2019 method takes advantage of differences in the DNA methylation patterns \u2014 which are important to control levels of genes \u2014 between mother and fetus.\n\u201cSuch a non-invasive approach will avoid the risk of miscarriages of normal pregnancies caused by current, more invasive procedures,\u201d the scientists wrote in their paper.\nDoctors currently use a test known as amniocentesis to check whether a baby is likely to be born with Down\u2019s.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "Commenting, Professor Andreas Meyer-Lindenberg, Central Institute of Mental Health, Mannheim and member of the ECNP executive board, said: \"This work builds on previous studies that have shown a critical role of excessive activity of subregions of the temporal lobe in the generation of voice hallucinations in schizophrenia.\nTo move this into treatment, controlled trial such as the one by Dollfus and coworkers are important.\n*This work has been accepted in the peer-reviewed journal Schizophrenia Bulletin: The Journal of Psychoses and Related Disorders.\nThe exact publication date has still to be determined.\nThe French research team worked with 26 patients who received active TMS treatment, and 33 as a control group, who received sham (placebo) treatment.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here, and we appreciated the discussion of prevalence of schizophrenia.", "answer": 1}, {"article": "\u201cCAR-T is not the EpiPen,\u201d he said.\nAnd childhood leukemia is just the start for a field that has attracted intense interest in academia and industry.\nAnd although checkpoint inhibitors are off the shelf, with every patient getting the same drug, CAR T-cell therapy is customized to an individual.\nIf the panel gives the nod, the agency probably will follow suit by the end of September.\nOnce inside the person\u2019s body, the T-cell army multiplies astronomically.\n", "question": "Does the story commit disease-mongering?", "explanation": "There\u2019s really no disease mongering here, though there is one point that we\u2019d like to single out. The story states that the CAR T-cell treatment \u201cinitially would be available only for the small number of children and young adults whose leukemia does not respond to standard care. Those patients typically have a grim prognosis\u201d [emphasis added]. What does it mean to \u201ctypically have a grim prognosis\u201d? It\u2019s a fine turn of phrase, but it doesn\u2019t actually convey much information \u2014 and it\u2019s scary. In a case like this, it would likely be better to let the numbers speak for themselves. Or, if a story does include this sort of language, to back it up with some numbers.", "answer": 1}, {"article": "For more information, visit us at allinahealth.org, Facebook, Twitter, YouTube or Healthy Set Go.\nHow to treat patients who have microinvasive breast cancer - tumors that are 1 mm or less in size (the thickness of a dime) -- is somewhat controversial.\nPhysicians at the Virginia Piper Cancer Institute wanted to know if surgical procedures to test the lymph nodes for cancer were always necessary.\nCan these tiny tumors affect the lymph nodes and spread cancer to other areas of the body?\nThe Virginia Piper Cancer Institute\u00ae, part of Allina Health, provides comprehensive care through all aspects of cancer prevention, early detection and treatment to help individuals maintain quality of life and find ways to live with and beyond cancer.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering. The management of microinvasive breast cancer \u2014 which includes assessing how it spreads \u2014 remains a common surgical dilemma.", "answer": 1}, {"article": "UCSF Benioff Children's Hospital Oakland (formerly Children's Hospital & Research Center Oakland) is a premier, not-for-profit medical center for children in Northern California, and is the only hospital in the East Bay 100% devoted to pediatrics.\nThis was a novel approach, different from the commonly used method of looking at zinc in the blood or using stunting and morbidity for assessing zinc status.\nIn addition to King, the study's other authors are Sarah J Zyba, Swapna V Shenvi, David W Killilea, Tai C Holland, Elijah Kim, Adrian Moy, Barbara Sutherland, Virginia Gildengorin, and Mark K Shigenaga, conducting the research at CHORI's Nutrition and Metabolism Center.\nThey used the parameter of DNA damage to examine the influence of a moderate amount of zinc on healthy living.\n\"These results present a new strategy for measuring the impact of zinc on health and reinforce the evidence that food-based interventions can improve micronutrient deficiencies worldwide.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no explicit disease mongering in this news release. However, the reference to \u201cexcessive DNA damage\u201d from insufficient zinc consumption and the statement that \u201cZinc also helps limit inflammation and oxidative stress in our body, which are associated with the onset of chronic cardiovascular diseases and cancers\u201d could plant fear in some readers\u2019 minds.", "answer": 1}, {"article": "A growing number of doctors are offering an expensive laser procedure they say zaps away a common fungus that causes ugly, discolored nails. Published data on laser treatment for nail fungus is scant, but early results suggest it is a reasonable option for people who don't want the side effects of oral medications.\n\nOnychomycosis, or fungal infection of nails\u2014most often on the toes\u2014affects about 12% of Americans, according to the American Academy of Dermatology. Some people are genetically prone to it. Others, including swimmers...", "question": "Does the story commit disease-mongering?", "explanation": "This is one story that does not commit disease-mongering of toenail fungus.\u00a0 It includes a discussion of the mild end of the spectrum \u2013 in which nail fungus is \u201cmerely a cosmetic problem.\u201d", "answer": 1}, {"article": "\u201cI\u2019ve had patients who wouldn\u2019t dream of not being treated,\u201d Dr. Berchuck said.\nMoreover, the extra chemotherapy seemed to worsen the quality of life.\nDoctors are convinced that if the initial diagnosis can be made early, which is very difficult, the cancer can be treated by surgery.\nThis new study does not refer to initial diagnosis of ovarian cancer, only to a relapse.\nThe finding is another in a series suggesting that early detection of cancer might not always lead to better outcomes for patients.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate the seriousness or prevalence of Ovarian Cancer.", "answer": 1}, {"article": "Research has shown that vitamin D plays a key role in maintaining muscle integrity and strength and some studies suggest vitamin D may reduce the risk of falls.\n\"Although these initial findings are encouraging, we need to confirm the results in a larger trial,\" Houston said.\nThe study is published in the early online edition (8/16/2015) of the Journal of the American Geriatrics Society.\nThe Wake Forest Baptist team currently is conducting a clinical trial to try to determine how vitamin D affects risk factors for falls such as balance and muscle strength and power.\nFunding for the study was provided by the Wake Forest Translational Science Institute and Center for Integrative Medicine and the Claude Pepper Older Americans Independence Center of Wake Forest Baptist.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release did not appear to exaggerate the severity of the problem.", "answer": 1}, {"article": "Researchers said they had identified a family of retroviruses in patients with chronic fatigue syndrome, opening up a potentially promising new avenue of treatment for a debilitating disease that afflicts as many as four million Americans and 17 million people world-wide.\n\nThe finding will likely spur patients with the condition to seek treatment with drugs used to fight HIV, the virus that causes AIDS. Although HIV and the newly identified virus group are different, they are both retroviruses.", "question": "Does the story commit disease-mongering?", "explanation": "", "answer": 0}, {"article": "Michael T. Lotze, a professor of surgery and bioengineering at the University of Pittsburgh, said that \"the work is heroic.\nA team of researchers from the National Cancer Institute reported yesterday that they have successfully treated two cancer patients using gene therapy, the introduction of genes into the human body for medical purposes.\n\"I think it is an important landmark to see some cancer patients respond to a gene therapy -- finally,\" said Patrick Hwu, a physician and gene-therapy researcher at the University of Texas M.D.\nResponse by others in the field was positive but not effusive.\nThe new report, however, is believed to be the first time that genetically engineered immune system cells -- specifically, T lymphocytes -- have produced the same effect.\n", "question": "Does the story commit disease-mongering?", "explanation": "Cancer has a scary connotation for most people. This story failed to inform the viewer about how common death from melanoma was. While they presented an estimate for the number of Americans that will be diagnosed with melanoma in 2006 (~ 60,000) there was no mention that it is estimated that there would be <8,000 deaths attributable to melanoma. This information is helpful for recognizing that melanoma is much less common and deadly than a number of other diseases. ", "answer": 0}, {"article": "Eating more fiber during adolescence was linked to a 16 percent lower risk of breast cancer overall, and a 24 percent lower risk of breast cancer before menopause.\nWhy would these foods have such an impact?\nEating more fruits and vegetables was especially beneficial, the researchers said.\nThe researchers from Harvard's T.H.\nThis is just one mechanism by which we can reduce risk and it does warrant further study.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "6 Kowdley KV, et al.\nThis ongoing, open-label study enrolled 90 children aged between six and 11 years with chronic HCV, mostly genotype 1 (n=86).\n\"This study is a breakthrough for the management of children aged six to 11 years old with Hepatitis C, demonstrating that the new DAA regimen is highly efficacious and, more importantly, safe in this group of HCV-infected children\", said Prof Frank Tacke, University Hospital Aachen, Germany, and EASL Governing Board Member.\nThe study, presented at The International Liver Congress\u2122 2017 in Amsterdam, The Netherlands, also showed that the fixed-dose combination of LDV/SOF was well-tolerated, and no patients experienced a serious adverse event considered related to the study drug.\n\"These data establish the use of the oral direct-acting antivirals as an important treatment option in HCV-infected children aged six to 11 years old.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease mongering. It notes the prevalence of hepatitis C among children, which \u201cvaries from 0.05%-0.36% in the United States and Europe and up to 1.8%-5.8% in some developing countries.\u201d It would have been even better with specific numbers.", "answer": 1}, {"article": "In the raw analysis, mothers who skipped the supplement were more than 2.1 times more likely to have a child with autistic disorder compared with mothers who took the supplement.\nYou can read a summary of the study and the editorial on the JAMA website.\nIt\u2019s unclear how these findings apply to mothers and children in the United States.\nThe researchers also found that the popularity of folic acid supplements rose as time went on.\nBut not all mothers were equally likely to take folic acid supplements.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story mentions the puzzlement about why rates of autism appear to be rising in the US, thus giving readers a sense of how much remains unknown about potential causes or responses.", "answer": 1}, {"article": "Patients taking briakinumab had more serious infections and more cancers than those taking methotrexate.\n\"Obviously, the price that this comes with is the increased rate of serious infections and cancers.\"\n\"Many of us were disappointed it was withdrawn because there would be a subset of patients who wouldn't respond to anything else and it would have been nice to have for them.\"\nThe study is published in the New England Journal of Medicine.\n\"We in dermatology have never spoken about remission before.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering of psoriasis here.", "answer": 1}, {"article": "Whitcomb, whose research on the determinants of fertility and pregnancy outcomes usually involves studying biomarkers at the molecular level, adds, \"Lifestyle is definitely relevant to these outcomes because it can have an effect at the molecular level.\nResults are in the current online issue of Human Reproduction.\nFurther study is necessary to clarify possible mechanisms through which walking and vigorous activity might affect time-to-pregnancy.\"\nWhat we eat and what we do are potential factors we can change to shape our health.\nWhitcomb says another way in which this study is distinct from other work in this area has to do with who was included in the study.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "Recently a well-known Seattle Seahawks player and four of his teammates are sitting out a week of training camp to receive a blood-healing treatment from a European supplier an IRAP-based treatment solution.\nIt's a non-drug, non-surgical treatment derived from your own blood.\nThe European-based process was the inspiration for Dr. Barreto of Oklahoma City, Oklahoma to work on developing a stronger, more effective, and more cost-efficient version in the United States.\nThis therapy has recently been highlighted by several professional football players traveling to Europe for treatment.\nThe cost of the USA-based IRAPjoint\u2122 treatment is $2,000 compared to the reported price of $10,000 for a foreign competitor.\n", "question": "Does the news release commit disease-mongering?", "explanation": "This was a tough call and we gave them the benefit of the doubt on this criteria. Although the release doesn\u2019t disease monger about joint pain, without a clear indication of who should get this injection, it may imply that anyone with joint pain could consider this treatment. And that\u2019s not the case.", "answer": 1}, {"article": "The American Orthopaedic Society for Sports Medicine (AOSSM) is the premier global, sports medicine organization representing the interests of orthopaedic surgeons and other professionals who provide comprehensive health services for the care of athletes and active people of all ages and levels.\n\"This type of osteochondral allograft transplantation has traditionally been used in younger active patients with cartilage disorders.\nHowever, seeing this type of success allows sports medicine physicians another option in older patients and serves as a predictable biologic joint preservation technique,\" said Crawford.\nA statistically significant improvement for both groups was noted for the final follow-up for IKDC and all five KOOS sub-scores.\nGreatest changes were seen in the ability of patients to perform Sports and with improvement in healthful daily activity.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no disease mongering. However, the story also doesn\u2019t provide any context on what this procedure is supposed to treat or the impact of that condition. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "Their average age was 69.\nA 60-year-old woman has a 44 percent lifetime risk of fracture due to low bone density.\nTUESDAY, Aug. 16, 2016 (HealthDay News) -- An experimental drug appears to reduce the risk of bone fractures in postmenopausal women with osteoporosis better than a placebo and the currently available drug, a new study finds.\n\"The bar is high for any preventive treatment -- in the efforts to prevent a fracture that may or may not ever occur, prescribers do not want to prescribe a therapy that causes a new problem.\nEven if a patient is insured, monthly copays can range from $30 to $400.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story shares the fact that\n\u201cA study based on 2010 U.S. Census data estimated that more than 3 million women between the ages of 50 and 69 have osteoporosis. A 60-year-old woman has a 44 percent lifetime risk of fracture due to low bone density.\u201d\nAn explanation of the term \u201clifetime risk\u201d would be helpful to the reader. (In this setting, it means\u00a0the probability of experiencing a fracture during the remaining years of life. In fact, the figure reported is really a \u201cresidual lifetime risk.\u201d)\nNow for a slight tangent: It is great that the story chose to report an absolute risk here rather than a relative risk. This is a point we at HealthNewsReview.org try to hammer home. In a 2007 article in the Journal of Bone and Mineral Research, Nguyen et. al. in their article titled \u201cResidual lifetime risk of fractures in women and men\u201d had the following comment on relative versus absolute risk:\nCommunication of risk in the osteoporosis field has traditionally relied on the concept of relative risk. However, relative risk can be misleading to patients and clinicians,(42) because the interpretation of a relative risk or its change is highly dependent on the baseline risk. For instance, doubling a minor risk is still minor, but doubling a common risk is alarming. It is therefore desirable that individuals who have BMD measurements be informed about their fracture probability risk category instead of their relative scores.(4) The lifetime risk estimates from this study provide such a means for communication of risk to an individual patient.", "answer": 1}, {"article": "\"I refuse to believe that there's going to be any other outcome than 'it's all going to be okay' because the alternative is unfortunately not something I want to think about.\"\nThe study, funded by Illumina, a maker of one non-invasive prenatal test, looked at eight women with abnormal test results.\nWhen Marin Mejia was pregnant with her son Owen, one such blood test that picks up DNA from mother and baby came back showing abnormal results.\nBut doctors told Mejia they needed to investigate what caused the irregular finding.\n\"If there is cancer, the tumor is shedding DNA into the mother's blood as well and that is what is accounting for this imbalance,\" study author Dr. Diana Bianchi, who serves on an advisory panel for the company, told CBS News.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story focuses on an individual woman\u2019s story, and provides no perspective on the rarity of her case. Although it may be an underestimate, cancer was reported in only\u00a00.008% of the samples analyzed. The story needed some acknowledgment that this is an exceedingly rare occurrence.", "answer": 0}, {"article": "There were 812 deaths (32.2 percent) among heart failure patients not treated with Plavix and 709 deaths (28.1 percent) among heart failure patients treated with Plavix.\nThe mean follow-up was 18 months for both heart failure groups and just over two years for both non-heart failure groups.\nA randomized study comparing conventional heart failure therapy with and without Plavix \"is needed urgently,\" the editorial writer concluded.\nThe study appears online March 23 and in the March 30 print issue of the Journal of the American College of Cardiology.\nMONDAY, March 22, 2010 (HealthDay News) -- The anti-clotting drug Plavix is of modest benefit in cutting the odds of death in patients with heart failure and heart attack who don't undergo angioplasty, a new study finds.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0Not applicable because there was really no discussion of heart failure incidence or seriousness. ", "answer": 2}, {"article": "I couldn't get anything done,\" Ham said.\nBut there's a problem: There is very little research showing marijuana works as a treatment for such addictions.\nBolstered by stories like Ham's, doctors are experimenting with marijuana as an addiction treatment in Massachusetts and California.\nIt would also be wrong to portray marijuana as completely safe, they say, because it can also be addictive.\nMany medical professionals say there's not enough evidence for them to confidently prescribe it.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no obvious disease mongering in this story. Opioid addiction is real and very problematic.", "answer": 1}, {"article": "In the 1970s, the FDA required warnings on drugs containing progesterone, as 17-HP does, because of an increased risk of birth defects.\nNot a huge dent, but a significant one.\nInterestingly, the drug is not new \u2014 it's just taken a long and circuitous route to approval.\nEveryone in this field is mindful of the long-running tragedy of vaginal and other cancers and male urinary disorders that resulted from the last drug thought to prevent premature birth \u2013 a synthetic estrogen called diethylstilbesterol, or DES.\nAnd even for the 30,000 or so women who are eligible, 17-HP, which will be marketed as Makena, isn't a magic bullet.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering of prematurity or its consequences.", "answer": 1}, {"article": "\"I think it's mostly positive news,\" Miglioretti said.\nTUESDAY, Feb. 22, 2011 (HealthDay News) -- In women who have had breast cancer, annual mammograms help detect second breast cancers, but they're not as effective in women who have never had the disease, new research suggests.\n\"Screening mammography does work well in women with a history of breast cancer, so they should continue to get their annual screening mammogram,\" said Diana Miglioretti, senior investigator at Group Health Research Institute in Seattle and a co-author of the new research.\n\"Despite poorer performance compared with women without a prior history of breast cancer, overall screening mammography was effective at detecting the majority of breast cancer in women with a [history] at an early favorable stage, with the majority of tumors being diagnosed as ductal carcinoma in situ or stage 1,\" Smith said.\nWithin a year of the screening, 655 cancers were found in women with a breast cancer history and 342 in those without.\n", "question": "Does the story commit disease-mongering?", "explanation": "The headline of this story misleads the reader by stating that \u201cMammograms May Not Be Fool-Proof at Catching Second Cancers.\u201d\u00a0 No type of screening for breast cancer is fool-proof whether it is for an initial diagnosis or for a second breast\u00a0cancer.\u00a0 Regarding the accuracy of screening mammography for an initial breast cancer diagnosis, the Komen for the Cure website states that in women age 50 and older \u201c\u2026between six and 27 percent of breast cancers may be missed by mammography alone.\u201d\u00a0 Mammography is most effective in women 50 and older.", "answer": 0}, {"article": "\"When a body gets used to having a chronic headache suppressor, the patient can experience a rebound in the absence of that suppressor.\nThe study received no funding from private industry.\nAnd, he said, the hope was that lidocaine would essentially short-circuit that bundle's headache-causing pathway.\nThe procedure didn't help everyone, though.\nMandato stressed that no one in the study required sedation to undergo the procedure.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article did not engage in disease mongering.", "answer": 1}, {"article": "WASHINGTON (Reuters) - An experimental drug being developed to fight influenza may fight a common but little-known virus called parainfluenza virus, researchers and the company said on Friday.\nBecause Fludase affects the human cells that viruses infect, not the virus itself, it is less likely to cause the virus to develop resistance, the company believes.\nAdding parainfluenza to its approved indications would provide a unique and potentially large market for San Diego-based NexBio.\n\u201cTherapies for parainfluenza are urgently needed,\u201d Moscona, an expert on parainfluenza viruses, said in a statement.\nMoscona said tests were needed that would show the drug actually helped reduce disease symptoms in animals.\n", "question": "Does the story commit disease-mongering?", "explanation": "       \n \nThe story fails to note that parainfluenza virus infections do not cause serious disease in the majority of people.\u00a0In doing so, it provides an overly disconcerting  picture of the virus and its potential to cause serious illness. The failure to provide background information in combination  with the initial quote of the lead author, \u201cTherapies for parainfluenza  are urgently needed,\" qualifies as disease-mongering. \n ", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070723/23healytip.htm was not found on this server.", "question": "Does the story commit disease-mongering?", "explanation": "The story did a bit of disease and treatment mongering.\u00a0 Describing these medications as \u2018lifesaving pills\u2019 which people take to protect themselves \u2018against the ravages of heart disease\u2019 sets a tone that is not conducive to helping readers think objectively about the research results being reported on.", "answer": 0}, {"article": "In recent years, emergency service dispatchers have been coaching callers in hands-only CPR rather than telling them how to alternate breaths and compressions.\nBut less than a third of victims get this essential help.\nThis action should be taken only for adults who unexpectedly collapse, stop breathing and are unresponsive.\nIn a major change, the American Heart Association said Monday that hands-only CPR - rapid, deep presses on the victim's chest until help arrives - works just as well as standard CPR for sudden cardiac arrest in adults.\nHad the situation been reversed, \"I wouldn't have known what to do.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "The segment does nothing to exaggerate the frequency or severity of sudden cardiac arrest. ", "answer": 1}, {"article": "\"If someone said to my husband, 'I know this has been a rough road for you, and a big impact on your sex life, but if she stays on it another five years.\nDoctors saw no increase in strokes, which has long been a concern with tamoxifen, Gray says.\nGray noted that tamoxifen has risks.\nThese drugs are slightly more effective than tamoxifen, although they don't work before menopause, Litton says.\nYet Shockney says her husband of nearly 35 years would have wanted her to do everything possible to survive.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no evidence of disease-mongering.", "answer": 1}, {"article": "Currently, deep brain stimulation is used to control the tremors associated with Parkinson's, symptoms of obsessive-compulsive disorder and some other psychiatric conditions, including depression.\n\"I think it was exciting that they were really able to show that stimulating that area was important for a certain kind of learning.\nThe study is published Feb. 9 in the New England Journal of Medicine.\nStimulation of the entorhinal cortex -- a region considered crucial to transforming daily experience into lasting memories -- produced the improvement, the researchers said.\n\"Our preliminary results provide evidence supporting a possible mechanism for enhancing memory, particularly as people age or suffer from early dementia.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate who might eventually benefit from this line of research.", "answer": 1}, {"article": "Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:\n\n\"Nivolumab is one of a new wave of immunotherapies that are beginning to have an impact across cancer treatment.\nIt was funded by Bristol Myers Squibb.\nThe ICR has an outstanding record of achievement dating back more than 100 years.\nFor enquiries out of hours, please call 07595 963 613.\nFirst awarded the status in 2006, it was re-awarded in 2011.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "What does that mean for men today?\nAnd men diagnosed with prostate cancer whose PSA is rising slowly may be ideal candidates for monitoring instead of surgery or other treatment, he added.\nThe work is \"another step on the road to more sophisticated\" prostate cancer screening and treatment, Dr. Timothy Church of the University of Minnesota wrote in an editorial accompanying the work.\nBut Carter contends the findings suggest that men should consider getting a baseline PSA test around age 40, instead of the more usual 50, to use as a comparison for future changes.\nWASHINGTON \u2014 Prostate cancer is more likely to be life-threatening if the man's PSA level rose rapidly during the years before he was diagnosed, says a new study that may help change how PSA tests are used.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article nicely describes the dilemma around whether or not to find and/or treat prostate cancer. Many prostate cancers are slow-growing and will never threaten a man's life.\u00a0 This is often lost in the enthusiasm over PSA testing.\u00a0 The article also provides some estimates of the number of men who will be diagnosed and die from prostate cancer this year, giving some framework for the relative burden of prostate cancer (or showing that despite a relatively larger number of men who will be diagnosed, a minority of them will die from the disease).\u00a0 However, the article misses an opportunity to emphasize or re-state what the numbers really mean and that they demonstrate there should be caution about widespread screening.\u00a0 ", "answer": 1}, {"article": "\u201cI\u2019m optimistic,\u201d Mr. Sugrue said one morning in September, after scheduling a second brain operation.\nThe new technique refines the art of opening the barrier: it uses microcatheters \u2014 fine, highly flexible tubes that are inserted into an artery in the groin and then threaded up into tiny blood vessels nearly anywhere in the brain \u2014 to spray chemotherapy directly onto tumors or areas from which they have been removed.\n\u201cThe early data is very interesting and exciting.\u201d\n\nThe complexity of a study like this goes beyond the science.\nscans of the first few patients showed that the treatment seemed to erase any sign of recurring glioblastomas.\nDr. Boockvar said microcatheters should increase the odds of success by delivering a high dose of the drug directly to where it was needed most.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article describes glioblastoma\u2019s deadliness with facts and data rather than appeals to emotion. The language is in some places dramatic but not inappropriately so. ", "answer": 1}, {"article": "\u201cWe need at least 1 \u00bd to 2 years\u2019 worth of data\u201d to make a meaningful judgment about how to proceed, Dr. Carter said.\nAside from cancer and prostatic growth with age, factors that can change PSA measurements include inflammation or infection of the prostate; a decline in testosterone levels or the drug finasteride, taken for hair loss, both of which lower the PSA; and variations in laboratory assays and in the inherent biology of a person.\nThat means that 2.25 percent of the total number of men with a PSA less than 4 had life-threatening cancers.\nBiological variability can result in as much as a 15 percent difference between readings, and in nearly half of men with an abnormal PSA, the test will normalize in one to four years without any treatment.\nIf more than 25 percent of the PSA is free, chances are that it is being produced by a benignly enlarged prostate.\n", "question": "Does the story commit disease-mongering?", "explanation": "There are several inaccuracies in the description of prostate cancer and prostate cancer screening.\u00a0 One, the story quotes a source who\u00a0attributes the drop in prostate cancer deaths to PSA screening, which is not known for sure (and there were advances in medical treatment at the same time even though this source states there weren't).\u00a0 There could be other reasons for the drop in prostate cancer deaths.\u00a0 Another inaccuracy is that the story states \"guidelines\" (without explaining which guidelines) recommend all men have an annual PSA test beginning at age 50.\u00a0 This is not true; in fact, major guideline-issuing organizations like the American Urological Association, the American Cancer Society, and the U.S. Preventive Services Task Force recommend a shared decision making approach which individualizes this choice based on personal preferences and values.\u00a0 Third, the idea of using PSA velocity in prostate cancer screening has not been well-studied and there is not a lot of evidence to prove the value of this approach.\u00a0 The article states using PSA velocity is a better approach than using a single test for prostate cancer screening, which has not yet been proven (although this approach is often used in monitoring advanced disease after diagnosis).\u00a0 Although a minor inaccuracy, the article also quotes a source who states that PSA does not fluctuate based on sexual activity.\u00a0 However, the evidence for this is mixed and not conclusive.\u00a0 ", "answer": 0}, {"article": "Wolters Kluwer N.V. (AEX: WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors.\nThe researchers believe the DTI technique may expand the options for older women, who are less likely to undergo breast reconstruction.\nThe authors note some important limitations of their study--particularly the fact that it was a review study of one hospital's experience with a relatively new procedure.\nDr. Moreira adds, \"In appropriately selected cases, DTI reconstruction is a viable alternative to staged techniques requiring multiple surgeries.\"\nClick here to read \"Direct-to-Implant Breast Reconstruction in Women Older than 65 Years: A Retrospective Analysis of Complication Rate and Overall Outcomes.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in this news release. However, the assumption of the release is that there is something wrong with the fact that most women older than 65 choose not to have breast reconstruction. And the implication is that these women would opt for reconstruction if it were more convenient than the current procedure. Maybe that is the case, but we don\u2019t know why they choose what they choose.\nReconstruction requires being under anesthesia for a long time and there are known risks associated with implants. It also takes a while before the implants feel \u201cnormal.\u201d None of these potential reasons for not having reconstruction surgery over age 65 were addressed in the release. That omission could suggest that women not opting for reconstruction is somehow a problem that needs to be remedied. And that\u2019s concerning if those women are simply making a sensible choice to forego a procedure that lacks medical need but carries higher risks.", "answer": 1}, {"article": "Toni Weiser is a veteran of skin-cancer removals. The 75-year-old retired teacher in Santa Fe, N.M., says she\u2019s had at least eight basal and squamous cell cancers scraped, frozen and surgically excised from her arms, face and shoulders.\n\nWhen a basal-cell cancer reappeared on Mrs. Weiser\u2019s nose last year, her dermatologist suggested a new, painless, nonsurgical treatment and she eagerly agreed. After 16 treatments with a small radiation device held millimeters from her nose, the tumor was gone. \u201cI felt nothing\u2014just some mild...", "question": "Does the story commit disease-mongering?", "explanation": "Basal or squamous cell cancers afflict more Americans annually than all other cancers combined, according to the story. \u00a0While generally not lethal, they require treatment, and that makes these types of cancers indeed a significant problem. What\u2019s key to remember is that this treatment really should only be considered for the face or other areas where standard excisional surgery is not feasible. The other element that the story could have emphasized is that it is recommend only for older individuals, >50.", "answer": 1}, {"article": "Professor Norman Ratcliffe said, \"There is currently no accurate test for prostate cancer, the vagaries of the PSA test indicators can sometimes result in unnecessary biopsies, resulting in psychological toll, risk of infection from the procedure and even sometimes missing cancer cases.\nA video in which Professor Probert explains how the machine works can be found here\nThe research team is now looking to fund a full clinical trial.\nAfter further sample testing the next step is to take this technology and put it into a user friendly format.\nAn accurate urine test would mean that many men who currently undergo prostate biopsy may not need to do so.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease mongering, but we were concerned that the release unjustly pushes the \u201curgency\u201d of the need for testing. More on that under the \u201cUnjustifiable language\u201d section below.", "answer": 1}, {"article": "\"The robot is the way to go,\" Jackson said.\nRecent concerns raised over the safety of medicated stents used in coronary angioplasty procedures have caused more patients and physicians to consider bypass surgery as a better therapy for blocked coronary arteries, said Chris Rabbitt, cardiac marketing director for the company.\nThe robots have proven popular for urologic, gynecologic and some general surgery, Pappas said, but few coronary surgeons use them for valve repairs and fewer still do bypass procedures.\nMany stents are infused with chemicals intended to keep the arteries open, but some studies suggest the medication introduces new risks to cardiac health.\nUsing robotics to bypass major blocked arteries and putting stents in other blocked arteries is gaining some currency, Rabbitt said, although few surgeons have come close to Srivastava's familiarity with the robot.\n", "question": "Does the story commit disease-mongering?", "explanation": "Quoting the marketing director of the company that makes the robotic systems, the story suggests that bypass surgery may be safer than using a stent to keep an artery open, generating fears about the safety of stents. The data about stent risk is complex and in dispute. This implication of greater risk from stenting should not have been reported unless it was investigated further.\u00a0", "answer": 0}, {"article": "While the disease is rare, with about 3,100 new diagnoses and 330 deaths in the United States each year, it often goes undiagnosed until it affects vision. Sacks \u2014 known for books including Awakenings and The Mind's Eye, in which he tells the story of his own cancer \u2014 said his symptoms hit suddenly, wiping out a triangular chunk of the vision in his right eye.", "question": "Does the story commit disease-mongering?", "explanation": "The story avoids disease-mongering, noting that ocular melanoma is rare.", "answer": 1}, {"article": "Normally it's the very old or very young that die from flu, but every year there are deaths from influenza A,\" said Gilbert.\nThe vaccine would be an important step in treating seasonal flu, not just pandemics.\nLondon, England (CNN) -- Researchers hope a new treatment developed in the United Kingdom will prove vital in controlling future flu pandemics such as H1N1 (swine) flu, bird flu as well as ending the need for annual flu jabs.\nThe initial results are positive, says Peter Palese, professor and chair of microbiology at Mount Sinai School of Medicine, New York, but more research is needed before the new treatment is approved.\nThe results, say Gilbert, are important in developing a new form of protection that researchers hope could spell the end of flu vaccination supply problems.\n", "question": "Does the story commit disease-mongering?", "explanation": "", "answer": 1}, {"article": "Some people (about 1 percent of whites; fewer of minorities) lack both copies of the CCR5 gene and are naturally resistant to HIV.\nThe sixth man also had modified cells, but fewer than expected.\nThe only side effect was two days of flulike symptoms.\nThe results announced Monday at a conference in Boston left experts cautiously excited.\n\"My results are excellent,\" he said.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "A viral vector is a virus that has been modified to deliver foreign genetic material into a cell.\n\"But they're not an easy group of patients to transplant.\"\n\"It's a good start, but I think we have better things coming down the road.\"\n\"Transplants are getting better but we need better therapy, there's no question.\"\nThe boy is currently on chemotherapy, the study authors noted.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story didn\u2019t exaggerate the consequences of Wiskott-Aldrich syndrome.", "answer": 1}, {"article": "\u201cIt felt as though my head was a cement block,\u201d Kaufman told NBC News.\nRelated: Placebos Help Kids with Migraine as Well as Drugs Do\n\nKudrow says that there is a reduction in the frequency and intensity of the headaches for a large number of his patients taking the new class of drugs, but not all.\nAccording to UCSF Medical Center, more than 35 million Americans suffer from migraine attacks.\nFor 63-year-old Lynn Kaufman, the battle against migraines consumed her life.\nAnother advantage: it could lead to a decrease in the amount of medications used by patients to handle headaches acutely.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story skirts the line here. The dramatic patient anecdote that leads the piece is not a typical presentation for a chronic migraine sufferer.\nHowever, the story redeems itself with a good description of the condition and its prevalence:\n\u2026more than 35 million Americans suffer from migraine attacks. About 4 million sufferers have chronic migraine, with headaches for 10 to 14 days a month. Most migraines are benign, although they can be disabling.", "answer": 1}, {"article": "\"It's not far-fetched that the pharmaceutical industry will try to create a supplement of these microbiomes, much like was done with probiotics,\" she said.\nIt's far too early to predict how this finding will play out in the future, but Kozyrskyj doesn't rule out the concept of a \"dog in a pill\" as a preventive tool for allergies and obesity.\nWhat's more, Kozyrskyj's study suggested that the presence of pets in the house reduced the likelihood of the transmission of vaginal GBS (group B Strep) during birth, which causes pneumonia in newborns and is prevented by giving mothers antibiotics during delivery.\n\"The abundance of these two bacteria were increased twofold when there was a pet in the house,\" said Kozyrskyj, adding that the pet exposure was shown to affect the gut microbiome indirectly--from dog to mother to unborn baby--during pregnancy as well as during the first three months of the baby's life.\nA new University of Alberta study showed that babies from families with pets--70 per cent of which were dogs--showed higher levels of two types of microbes associated with lower risks of allergic disease and obesity.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no obvious disease mongering here, but the release might plant the suggestion that if readers don\u2019t own a dog and don\u2019t expose their infant to dog-related bacteria, then they may be exposing their children to a greater risk of some form of allergy or even obesity later on. It\u2019s important for releases about association studies like this one was to describe the prevalence of a disease or condition so that people have a sense of what the normal rate of allergies might be in households with or without a dog.", "answer": 0}, {"article": "Barua is with the Kansas City (Mo.)\nDr. Rajat Barua, the paper's corresponding author, says the study is also noteworthy because of its finding that administering the right dose is critical: Treating \"low T\" but not restoring levels to normal doesn't appear to impart much benefit, at least in terms of cardiovascular risk.\nWhile the new study results do seem to advocate for testosterone replacement therapy, Barua stresses the need for \"appropriate screening, selection, dosing, and follow-up of patients to maximize the benefit of testosterone therapy.\"\nSo far, the medical community lacks results from any definitive clinical trial that might provide clear guidance.\nMore research is needed, they say, to clarify how testosterone affects the cardiovascular system.\n", "question": "Does the news release commit disease-mongering?", "explanation": "We are of two minds on this criterion. The news release leads the reader to infer that low testosterone levels are a health problem, but the existing research in this area offers only mixed support for that.\u00a0 If testosterone levels indeed are causally related to heart attacks and strokes, then this study has identified a substantive health issue.\u00a0 But it is not clear that existing research makes that conclusion possible.\nTo the release\u2019s credit, it does specifically warn that\u00a0doctors should not write a prescription simply because an older man is complaining of symptoms such as low energy and low sex drive. In this sense, it does push back to some extent against drug company promotional efforts surrounding \u201clow T,\u201d which we\u2019ve previously flagged for disease-mongering.", "answer": 1}, {"article": "But researchers at Johns Hopkins suggest that a common diagnostic technique doesn't help doctors much for patients whose chronic lower back pain appears to be due to arthritis of the joints in the spine.\nNeither is figuring out the cause of chronic back pain a lot of the time.\nCoping with an aching back isn't easy.\nDoctors may not change their approach anytime soon, however.\nDoing away with a painkilling injections, or nerve blocks, as a test to determine the root cause of the back pain didn't hurt patients who went on to have their pain treated by zapping nerves with electrodes.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0No disease-mongering.\u00a0 The story was about pinpointing causes of low back pain \u2013 a condition as broad as the ocean. ", "answer": 1}, {"article": "\u201cA.A.\n\u201cAlthough the randomized controlled trial is the gold-standard methodology in comparing between conditions,\u201d said Thomas G. Brown, an assistant professor of psychiatry at McGill University, \u201cit washes out a factor that may be important in potentiating A.A.\u2019s benefits, namely patient choice and preference.\u201d In other words, having a patient choose the form of treatment, rather than being assigned to it as in most studies, could be an important factor.\nThe paper was published last week in The Cochrane Library, a journal devoted to systematic reviews of health care interventions.\nDespite the largely negative findings, John F. Kelly, a clinical psychologist at Harvard, said he still believed that A.A. and other 12-step programs were effective.\nThe review covered only carefully controlled trials.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering. The story appropriately provides information from the study and discusses contributing factors of alcohol dependence, including genetics, environmental causes and/or emotional stress. ", "answer": 1}, {"article": "Chemotherapy and other cancer therapies can wreak havoc on the taste buds and olfactory senses, depriving recipients of the intricate interplay between taste and smell that is critical to grasping flavors and enjoying foods.\nTheir findings could bring relief to millions of patients undergoing cancer treatment.\nThe team's findings will make it possible for cancer patients to taste foods properly and to enjoy a healthier appetite, enabling more optimal nutrition during a critical period of recovery.\nThis research could help us develop TSA-targeted biomarkers and strategies for improving quality of life during chemotherapy.\nAlthough TSA is widespread and a frequent complaint of cancer patients, until now, there have been no established therapies that reliably prevent or treat this problem.\n", "question": "Does the news release commit disease-mongering?", "explanation": "This news release does not disease monger. Rather, it clearly states that TSA in cancer patients is a common problem, and can be detrimental to cancer patients\u2019 recovery.", "answer": 1}, {"article": "For more information on the field of anesthesiology, visit the American Society of Anesthesiologists online at asahq.org.\nAdditional research is needed to identify which women are more likely to experience severe labor pain and who would benefit the most from effective labor pain-control strategies to help reduce the risk and affect of pain on postpartum recovery.\nAnd, therefore, alleviating this pain might help reduce the risk for postpartum depression.\n\u201cPostpartum depression can develop from a number of things including hormonal changes, psychological adjustment to motherhood, social support, and a history of psychiatric disorders.\u201d\n\nLabor pain may be more problematic for some women than others, the authors note.\nAfter accounting for these factors, the study found that in some women, labor pain was still a significant risk factor for postpartum depression symptoms.\n", "question": "Does the news release commit disease-mongering?", "explanation": "We found the statement that labor pain \u201cmay be psychologically harmful for some women and play a significant role in the development of postpartum depression\u201d a gratuitous assessment, especially given that humans have been bearing children for hundreds of thousands of years without modern analgesics. This statement might scare women away from a perfectly viable alternative, i.e. birth without medicated pain relief.", "answer": 0}, {"article": "Traditionally, patients with leukemia, lymphoma and myeloma have first tried to find an adult bone marrow donor either from a close relative or from a national bone marrow registry.\nBut Tirpak's physician, Dr. Mary Laughlin, turned to something deemed medical waste until recently: umbilical cord blood.\nWell worth it, say Mumford and Tirpak, who received her stem cell injection two years ago.\nAnd patients still must endure months of recovery.\nSiblings are the best matches.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article does not appear to engage in disease-mongering.", "answer": 1}, {"article": "\u201cThis cost saving can be both to the individual, and if appropriate, to the insurance companies that may provide individuals with assistive devices.\u201d\n\nPartners in research: This work was supported in part by the Vision Health Research Network, the Fonds de recherche du Qu\u00e9b\u00e9c - Sant\u00e9, the Antoine Turmel Foundation, CRIR, and the MAB-Mackay Foundation.\nThe study's third co-author is Julie-Andr\u00e9e Marinier, from the Centre de recherche interdisciplinaire en r\u00e9adaptation du Montr\u00e9al m\u00e9tropolitain and \u00c9cole d'optom\u00e9trie at the Universit\u00e9 de Montr\u00e9al.\nFor the study, the Concordia-based research team recruited 100 participants who ranged in age from 24 to 97.\nA little over half the participants had age-related macular degeneration, a disease characterized by the deterioration of the small central portion of the retina that is normally responsible for fine detailed vision tasks such as reading.\nNewswise \u2014 Montreal, March 22, 2016 \u2014 The proportion of older adults with age-related vision loss is estimated to be as high as one in three over the age of 50.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in the release. It provides an accurate overview of how often age-related vision loss occurs.", "answer": 1}, {"article": "Editor: Jadwiga Wedzicha, MD, professor of respiratory medicine at the National Heart and Lung Institute (Royal Brompton Campus), Imperial College London, UK.\nIn the current study, 251 pregnant women who smoked were randomly assigned at 13 to 23 weeks of gestation to either receive vitamin C (125 women) or a placebo (126 women).\nThe authors believe that future trials of vitamin C supplementation in pregnant smokers should determine whether the benefits are greater if the supplementation starts earlier and continues postnatally in the babies themselves.\n\u201cFinding a way to help infants exposed to smoking and nicotine in utero recognizes the unique dangers posed by a highly advertised, addictive product and the lifetime effects on offspring who did not choose to be exposed.\u201d\n\nIn a previous study, the authors had shown that 72 hours after birth, babies of mothers who smoked had better lung function if their mothers were randomized to vitamin C (500 mg/day) during their pregnancies compared to those born to mothers who smoked and were randomized to placebo.\nIn \u201cOral Vitamin C (500 mg/day) to Pregnant Smokers Improves Infant Airway Function at 3 Months: A Randomized Trial,\u201d Cindy T. McEvoy, MD, MCR, and her co-authors report that at three months of age, the infants whose mothers took 500 mg of vitamin C in addition to their prenatal vitamin had significantly better forced expiratory flows (FEFs).\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release doesn\u2019t engage in disease mongering \u2014 there\u2019s a recognized association between smoke exposure and adverse health effects in children. But nor does it give us any idea of the scope of the problem. According to the Centers for Disease Control and Prevention (CDC), about 10% of expectant mothers surveyed said they smoked during the last 3 months of their pregnancy.", "answer": 2}, {"article": "But when it recurs and becomes metastatic, it's very difficult to treat,\" she explained.\n\"This is a new book.\nIn the meantime, she pointed out, a woman walking through a clinic door who is diagnosed with triple-negative breast cancer shouldn't panic.\nThis means that many currently available drugs simply won't affect it.\nThis was a phase 2 trial.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering.", "answer": 1}, {"article": "Further,Dr.\nWe\u2019d exhausted the other options in trying to control his cholesterol.\u201d\n\nTwo months after he started his biweekly injections of the new drug, Mr. Brown\u2019s LDL cholesterol level was down to 111 \u2013 not quite normal, which is 100 or less \u2013 but an almost 50 percent reduction from the level it had been for years.\nEven with this trio of medicines, Mr. Brown\u2019s LDL cholesterol level hovered around 200.\nMr. Brown had been part of a clinical trial testing the safety and effectiveness of one of the new PCSK9 inhibitors and, when the drugs were approved, Dr. Khera began working to get Mr. Brown approved by his insurance to be on the new regimen.\n\u201cBut Mr. Brown is the perfect patient for PCSK9 inhibitors.\n", "question": "Does the news release commit disease-mongering?", "explanation": "This is a close call but we think it crosses the line to Not Satisfactory. We stated this above, but it bears repeating: High levels of cholesterol, especially high levels of LDL cholesterol relative to high-density lipoprotein cholesterol, are widely considered a significant risk factor for heart disease. However, it is only a risk factor \u2014 it is not a disease in itself. The release refers to \u201cdangerously high levels of cholesterol\u201d in its opening paragraph, and it focuses on the story of a patient with familial hypercholesterolemia \u2014 a condition that is known to cause premature heart disease. But it never tells readers that cholesterol is only a risk factor and doesn\u2019t give any insight into how common this condition is or how worried the average reader should be about it.\u00a0\u201cThere are many more Frank Browns out there \u2013 patients who can\u2019t control their cholesterol with the standard drugs,\u201d the release says. How many?", "answer": 0}]